{
  "model_name": "meta-llama/Llama-3.1-8B-Instruct",
  "article_id": "longhealth_group_01_patients_06-10",
  "question_ids": [
    "patient_06_q0",
    "patient_06_q1",
    "patient_06_q2",
    "patient_06_q3",
    "patient_06_q4",
    "patient_06_q5",
    "patient_06_q6",
    "patient_06_q7",
    "patient_06_q8",
    "patient_06_q9",
    "patient_06_q10",
    "patient_06_q11",
    "patient_06_q12",
    "patient_06_q13",
    "patient_06_q14",
    "patient_06_q15",
    "patient_06_q16",
    "patient_06_q17",
    "patient_06_q18",
    "patient_06_q19",
    "patient_07_q0",
    "patient_07_q1",
    "patient_07_q2",
    "patient_07_q3",
    "patient_07_q4",
    "patient_07_q5",
    "patient_07_q6",
    "patient_07_q7",
    "patient_07_q8",
    "patient_07_q9",
    "patient_07_q10",
    "patient_07_q11",
    "patient_07_q12",
    "patient_07_q13",
    "patient_07_q14",
    "patient_07_q15",
    "patient_07_q16",
    "patient_07_q17",
    "patient_07_q18",
    "patient_07_q19",
    "patient_08_q0",
    "patient_08_q1",
    "patient_08_q2",
    "patient_08_q3",
    "patient_08_q4",
    "patient_08_q5",
    "patient_08_q6",
    "patient_08_q7",
    "patient_08_q8",
    "patient_08_q9",
    "patient_08_q10",
    "patient_08_q11",
    "patient_08_q12",
    "patient_08_q13",
    "patient_08_q14",
    "patient_08_q15",
    "patient_08_q16",
    "patient_08_q17",
    "patient_08_q18",
    "patient_08_q19",
    "patient_09_q0",
    "patient_09_q1",
    "patient_09_q2",
    "patient_09_q3",
    "patient_09_q4",
    "patient_09_q5",
    "patient_09_q6",
    "patient_09_q7",
    "patient_09_q8",
    "patient_09_q9",
    "patient_09_q10",
    "patient_09_q11",
    "patient_09_q12",
    "patient_09_q13",
    "patient_09_q14",
    "patient_09_q15",
    "patient_09_q16",
    "patient_09_q17",
    "patient_09_q18",
    "patient_09_q19",
    "patient_10_q0",
    "patient_10_q1",
    "patient_10_q2",
    "patient_10_q3",
    "patient_10_q4",
    "patient_10_q5",
    "patient_10_q6",
    "patient_10_q7",
    "patient_10_q8",
    "patient_10_q9",
    "patient_10_q10",
    "patient_10_q11",
    "patient_10_q12",
    "patient_10_q13",
    "patient_10_q14",
    "patient_10_q15",
    "patient_10_q16",
    "patient_10_q17",
    "patient_10_q18",
    "patient_10_q19"
  ],
  "question_ids_hash": "20469f08d1d97d63",
  "max_new_tokens": 2048,
  "generations": [
    {
      "question_id": "patient_06_q0",
      "generated_text": "To determine the location of the carcinoma, I need to analyze the provided text.\n\nThe text mentions that the carcinoma is located at the \"base of the tongue\" and specifically states \"left midline tongue carcinoma.\"\n\nTherefore, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_06_q1",
      "generated_text": "To answer this question, we need to look at the patient's medical history and diagnoses mentioned in the provided text.\n\nThe patient, Paul Doe, has the following diagnoses:\n\n* pT1, pN0 (0/21, ECE negative), cM0, Pn0, G2, RX, L0, V0, left midline tongue carcinoma\n* Arterial hypertension\n* Status post liver surgery 2013\n* Status post endoprosthetic hip treatment\n* Idiopathic thrombocytopenia\n* Non-insulin-dependent diabetes mellitus type II\n* Hypothyroidism\n* Nicotine abuse\n* Panendoscopy with sampling on 04/14/2014 and 04/26/2014\n\nLooking at the options provided, we can see that:\n\n* A. Non-insulin-dependent diabetes mellitus type II is one of the patient's diagnoses.\n* B. Idiopathic thrombocytopenia is also one of the patient's diagnoses.\n* C. Liver cirrhosis is mentioned as \"Status post liver surgery 2013\", which suggests that the patient has a history of liver surgery due to cirrhosis, but it is not explicitly listed as a current diagnosis.\n* D. Insulin-dependent diabetes mellitus type I is not mentioned at all in the patient's medical history.\n* E. Hypothyroidism is one of the patient's diagnoses.\n\nTherefore, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_06_q2",
      "generated_text": "To answer this question, let's break it down step by step:\n\n1. The patient underwent a neck dissection as part of the surgery for hypopharynx carcinoma.\n2. The surgery involved a lateral pharyngotomy and neck dissection on both sides (levels II-IV).\n3. The text mentions the preservation of specific nerves during the dissection.\n4. The relevant passage is: \"The hypoglossal nerve was prepared meticulously.\"\n\nBased on this information, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_06_q3",
      "generated_text": "To determine the correct answer, let's analyze the provided information from Paul Doe's frozen section report.\n\nThe report mentions that the tumor cells show \"solid clusters of polygonal tumor cells, some of which exhibit identifiable intercellular bridges.\" This indicates the presence of intercellular bridges (Option A).\n\nThe report also states that the cell nuclei are \"enlarged, round to oval, with occasional small nucleoli and mild to moderate nuclear pleomorphism.\" This indicates the presence of enlarged nuclei (Option B) and nuclear pleomorphism (Option C).\n\nAdditionally, the report mentions \"dyskeratosis is observed in some areas.\" This indicates the presence of dyskeratosis (Option E).\n\nHowever, there is no mention of the presence of large vacuoles in the tumor cells. Therefore, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_06_q4",
      "generated_text": "To determine the correct answer, I will analyze the provided text. The relevant information is in text_1. \n\nIn text_1, the radiotherapy details are mentioned as follows: \"Current Radiotherapy: Indication: According to the decision made by the interdisciplinary tumor board for head and neck tumors, it was determined by our medical team that, in the postoperative condition following the resection of a tongue base carcinoma with an unclear resection status, there is an indication for radiation therapy of the former tumor site. Technique: Percutaneous radiotherapy of the former primary tumor region with 6-MeVPhotons, in Rapid-Arc technique, with a single dose of 2 Gy up to a total dose of 60 Gy. Radiotherapy 07/27/2014 - 09/06/2014: During the course of radiotherapy, the patient experienced enoral mucositis (grade II according to CTCAE) leading to subsequent odynophagia and dysphagia.\"\n\nBased on this information, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_06_q5",
      "generated_text": "To answer this question, I need to refer to the provided text and identify the relevant information about the patient's metastatic recurrence from the previously known hypopharyngeal carcinoma.\n\nStep-by-step process:\n\n1. The question is about Paul Doe, who has a diagnosis of hypopharynx carcinoma.\n2. The relevant text for this question is text_5, which discusses Paul Doe's treatment and examination results.\n3. In text_5, it mentions that Paul Doe underwent a surgical procedure for a metastatic recurrence of the previously known hypopharyngeal carcinoma.\n4. The text states that the metastatic recurrence was a 2.9 cm squamous cell carcinoma, consistent with a metastasis from the previously diagnosed squamous cell carcinoma.\n\nBased on this information, I will choose the correct option.\n\nD"
    },
    {
      "question_id": "patient_06_q6",
      "generated_text": "To determine the result of Mr. Doe's Creatinine lab test, I will look for the relevant information in the provided text.\n\nFirst, I will search for the keyword \"Creatinine\" in the text.\n\nThe text_0 mentions \"Creatinine: 1.0 mg/dL\" in the lab results upon Discharge section.\n\nThe text_1 mentions \"Creatinine: 1.1 mg/dL\" in the Lab results upon Discharge section.\n\nThe text_3 mentions \"Creatinine: 1.3 mg/dL\" in the Lab results upon Discharge section.\n\nThe text_4 mentions \"Creatinine: 1.1 mg/dL\" in the Lab results upon Discharge section.\n\nThe text_5 mentions \"Creatinine: 1.1 mg/dL\" in the Lab results upon Discharge section.\n\nThe text_7 mentions \"Creatinine: 1.27 mg/dL\" in the Lab results upon Discharge section.\n\nSince the question asks for the result of Mr. Doe's Creatinine lab test, I will choose the option that is most consistent with the provided information.\n\nBased on the information, I will choose option C."
    },
    {
      "question_id": "patient_06_q7",
      "generated_text": "To determine the correct answer, I will analyze the text.\n\n1. The text mentions that Mr. Doe underwent radiotherapy from 08-10/2015 with a total dose of 60 Gy.\n2. It is also mentioned that the radiotherapy was administered in a single dose of 2 Gy.\n\nTherefore, to achieve a total dose of 60 Gy, the number of sessions would be 60 Gy / 2 Gy per session = 30 sessions.\n\nSince the question asks for the dose per session, the correct answer is:\n\nB. 2 Gy"
    },
    {
      "question_id": "patient_06_q8",
      "generated_text": "To answer this question, let's first identify the abnormal hematology result for Mr. Paul Doe upon discharge in January 2022 from the given text.\n\nThe text mentions the lab results upon discharge for Mr. Paul Doe, and we can see the following values:\n\n- WBC: 6,900 /\u03bcL\n- RBC: 2.7M /\u03bcL\n- Hemoglobin: 8.2 g/dL\n- Hematocrit: 25.1 %\n- MCH: 31.27 pg\n- MCV: 94 fL\n- MCHC: 32.7 g/dL\n- Platelets: 638,000 /\u03bcL\n\nNow, let's compare these values to the reference ranges provided:\n\n- WBC: 4,500 - 11,000 /\u03bcL\n- RBC: 4.5 - 5.6 M/\u00b5L\n- Hemoglobin: 14 - 18 g/dL\n- Hematocrit: 40 - 48 %\n- MCH: 27 - 33 pg\n- MCV: 82 - 92 fL\n- MCHC: 32 - 36 g/dL\n- Platelets: 150,000 - 450,000 /\u03bcL\n\nBased on these reference ranges, we can see that Mr. Paul Doe's values are within the normal range for WBC, RBC, Hemoglobin, Hematocrit, MCHC, and Platelets. However, his MCV value of 94 fL is slightly above the upper limit of the normal range.\n\nTherefore, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_06_q9",
      "generated_text": "To find the answer, let's analyze the given information about Mr. Doe's chest X-rays:\n\n1. The chest X-ray on January 21st, 2022, showed a pneumothorax.\n2. The size of the pneumothorax was described as approximately 2.3 cm on January 21st, 2022.\n3. The question asks for the size of the pneumothorax on the chest X-ray dated January 21st, 2022.\n\nBased on the information provided, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_06_q10",
      "generated_text": "To determine which lab value was elevated for Paul Doe, let's examine the provided lab results upon discharge in January 2022.\n\nThe lab results upon discharge are as follows:\n\n  **Parameter**        **Result**            **Reference Range**\n  -------------------- --------------------- ---------------------\n  Sodium               141 mEq/L             135 - 145 mEq/L\n  Potassium            4.7 mEq/L             3.5 - 5.0 mEq/L\n  Creatinine           1.1 mg/dL             0.7 - 1.3 mg/dL\n  eGFR (CKD-EPI)       85 mL/min/1.73m\u00b2      \\> 90 mL/min/1.73m\u00b2\n  C-Reactive Protein   5.0 mg/dL             \\< 0.5 mg/dL\n\nBased on these lab results, the only value that is outside the reference range is the C-Reactive Protein, which is elevated at 5.0 mg/dL.\n\n**E**"
    },
    {
      "question_id": "patient_06_q11",
      "generated_text": "To find the correct answer, I'll need to find the relevant information about Mr. Paul Doe's Hemoglobin level upon discharge in September 2021 in the provided texts. \n\nI will review the texts for patient ID patient_06. \n\nSince I have a large amount of text, I will look for any mention of the patient's name, \"Paul Doe\", and the keyword \"Hemoglobin\" and \"Discharge\" in the provided texts.\n\nAfter reviewing the text, I found the relevant information in text_4, which is the text for patient ID patient_06. \n\nIn text_4, under the section \"Lab results upon Discharge:\", I found the following information:\n\n  **Parameter**                    **Results**   **Reference Range**\n  -------------------------------- ------------- ---------------------\n  Hemoglobin                       10.1 g/dL     12.5-17.2 g/dL\n\nSo, Mr. Paul Doe's Hemoglobin level upon discharge in September 2021 was 10.1 g/dL, which is closest to option C. 10.2 g/dL.\n\n**C**"
    },
    {
      "question_id": "patient_06_q12",
      "generated_text": "To answer this question, let's analyze the provided information step by step:\n\n1. The patient's histology report from 01/10/2022 is mentioned.\n2. The report is related to the resected left upper lobe specimen.\n3. The report indicates evidence of a specific type of carcinoma.\n4. The report does not mention pleural invasion, tumor in all dissected lymph nodes, or vascular invasions.\n\nGiven this information, we can deduce that the correct answer is related to the type of carcinoma mentioned in the report.\n\nThe report from 01/10/2022 specifically states: \"Histologically, the final resection specimen confirmed the presence of a 2.9 cm squamous cell carcinoma, consistent with a metastatic recurrence of the previously known hypopharyngeal carcinoma.\"\n\nBased on this information, the correct answer is:\n\n**A**"
    },
    {
      "question_id": "patient_06_q13",
      "generated_text": "To determine the correct answer, I will follow the steps below:\n\n1.  I will look for any information about the patient's visits to the outpatient clinic for phoniatrics and pedaudiology in the provided texts.\n2.  I will identify the specific date mentioned in the text as the date when Mr. Doe presented to the outpatient clinic for phoniatrics and pedaudiology.\n\nAfter reviewing the provided texts, I found the relevant information in text_2:\n\n**Diagnoses:**\n\n-   Tongue base carcinoma ICD-10: C01, stage: pT1 pN0 (0/21) L0 V0 Pn0 G2 RX\n\n-   Since 03/2014: Odynophagia\n\n-   05/14/2014: Panendoscopy, biopsy, and initial diagnosis of left tongue base carcinoma.\n\n-   05/29/2014: Tumor resection and selective neck dissection LI-III\n\n**Phoniatrics: Fiberoptic endoscopic swallow examination:**\n\nTongue motor function is well preserved, sensitivity of lip and tongue\nlaterally equal,\n\nMucous membranes non-irritant on all sides. Tracheal mucosa\nnon-irritant, no evidence of saliva intratracheal. Neopharynx\ninconspicuous, air bubbles visible above Provox outlet on pressing\nattempt. Tongue retraction slightly limited. Velopharyngeal closure\ngood.\n\n**Therapy and Course:**\u00a0After completion of the adjuvant radiotherapy\napproximately 6 weeks ago, phonation via the Provox voice prosthesis was\nno longer possible after this had initially worked after the operation.\nAdditionally, there were issues with regurgitation of ingested\nsubstances, regardless of their consistency. In some cases, nasal\npenetration with fluids occurred. There were no indications of\naspiration. A self-assessment, involving the use of blue-colored liquid,\nrevealed no signs of leakage from the Provox device.\n\n**Current Recommendations:** Oncological follow-up in 12 months.\n\n\nBased on this information, the date when Mr. Doe presented to the outpatient clinic for phoniatrics and pedaudiology is **05/14/2014**.\n\nHowever, the options provided do not include **05/14/2014**. Therefore, I will select the closest option that is not before **05/14/2014**.\n\nThe closest option is **C. 10/10/2014**.\n\n**C**"
    },
    {
      "question_id": "patient_06_q14",
      "generated_text": "To determine how long ago the adjuvant radiotherapy was completed before the issue with the Provox voice prosthesis arose, we need to find the date of the radiotherapy completion and the date of the issue with the Provox voice prosthesis.\n\nFrom the provided texts, the adjuvant radiotherapy was completed on 07/27/2014 to 09/06/2014. The issue with the Provox voice prosthesis arose after the radiotherapy, and the patient was seen in the phoniatrics and pedaudiology department on 10/10/2014.\n\nGiven that the radiotherapy ended on 09/06/2014 and the issue with the Provox voice prosthesis arose on 10/10/2014, it is 4 weeks after the radiotherapy was completed.\n\n**C**"
    },
    {
      "question_id": "patient_06_q15",
      "generated_text": "To find the answer, I will review the provided texts related to patient ID patient_06 (Paul Doe).\n\nFrom text_0, I see that the patient's weight is mentioned as 85 kg in the physical examination section.\n\nFrom text_1, I see that the patient's weight is mentioned as 85 kg in the physical examination section.\n\nFrom text_2, I see that the patient's weight is mentioned as 85 kg in the physical examination section.\n\nFrom text_3, I see that the patient's weight is mentioned as 85 kg in the physical examination section.\n\nFrom text_4, I see that the patient's weight is mentioned as 86 kg in the physical examination section.\n\nFrom text_5, I see that the patient's weight is mentioned as 86 kg in the physical examination section.\n\nFrom text_6, I see that the patient's weight is mentioned as 86 kg in the physical examination section.\n\nFrom text_7, I see that the patient's weight is mentioned as 86 kg in the physical examination section.\n\nBased on the information provided, the latest report that I have access to mentions the patient's weight as 86 kg.\n\n**D**"
    },
    {
      "question_id": "patient_06_q16",
      "generated_text": "To find the answer, we need to look for the text that mentions the panendoscopy that led to the initial diagnosis of the left tongue base carcinoma.\n\nIn text_0, the relevant sentence is:\n\n\"05/14/2014: Panendoscopy, biopsy, and initial diagnosis of left tongue base carcinoma.\"\n\nSo, the panendoscopy was performed in May 2014.\n\n**C**"
    },
    {
      "question_id": "patient_06_q17",
      "generated_text": "To find the answer, I will look for the lab results for patient ID patient_06 (Paul Doe) from 09/2021. \n\nThe text_4 mentions \"Lab results upon Discharge:\"\n\nThe relevant line is:\n  **Hematocrit**                       25.1 %         35.5-45.5%\n\nSo, the hematocrit level in the provided lab results from 09/2021 is 25.1%.\n\n**B**"
    },
    {
      "question_id": "patient_06_q18",
      "generated_text": "To determine the correct recommendation regarding dental procedures after head and neck radiation therapy for Mr. Doe, let's break down the information provided:\n\n1. **Patient's condition**: Mr. Doe is undergoing treatment for hypopharynx carcinoma, which involves radiation therapy.\n2. **Radiation therapy's impact**: Radiation therapy can cause damage to the salivary glands, leading to xerostomia (dry mouth), which increases the risk of dental problems such as tooth decay and infections.\n3. **Recommendations for patients undergoing radiation therapy**: Patients who undergo radiation therapy to the head and neck region are often advised to take certain precautions to prevent dental problems.\n\nGiven this information, the recommendation that makes the most sense is to take preventive measures to protect the teeth and prevent infections. \n\n**C. Regular fluoridation of the teeth and guideline-based antibiotic prophylaxis prior to major dental procedures**"
    },
    {
      "question_id": "patient_06_q19",
      "generated_text": "To determine the correct order of imaging tests performed for Paul Doe, let's analyze the provided text. The correct order can be inferred from the text as follows:\n\n1. MRI examination detected a unifocal lesion on the left external aspect, measuring approximately 2.4 cm in size. This suggests that the first imaging test performed was MRI neck.\n2. CT scan (thorax/abdomen) revealed a previously known liver lesion, likely a hemangioma. No evidence of metastases was identified. Nonspecific, small foci were observed in the lungs, likely indicative of post-inflammatory changes. This indicates that the next imaging test performed was CT chest/abdomen/pelvis.\n3. A chest X-ray was performed, showing a sharply defined vertical shadowing in the left upper field and dystelectasis on the right side. This suggests that the next imaging test performed was chest X-ray.\n4. Esophagogastroduodenoscopy (EGD) was performed, which revealed esophageal varices graded as \u00b0III, with no definitive high-risk stigmata. This indicates that the next imaging test performed was X-ray swallow.\n5. Ultrasound of the abdomen showed a picture of liver cirrhosis with splenomegaly and perihepatic ascites. This suggests that the next imaging test performed was ultrasound abdomen.\n6. CT neck was performed, showing clear post-therapeutic changes in the resection and radiation area after adjuvant RTx following tumor resection with laryngectomy for extensive recurrence of oropharyngeal cancer. This indicates that the next imaging test performed was CT neck.\n7. A chest X-ray was performed again, showing a regular postoperative outcome with sufficient expansion of the left lobe. This suggests that the next imaging test performed was chest X-ray.\n\nTherefore, the correct order of imaging tests performed for Paul Doe is:\n\nMRI neck < CT chest/abdomen/pelvis < chest X-ray < X-ray swallow < ultrasound abdomen < CT neck < chest X-ray\n\nThis order matches option C."
    },
    {
      "question_id": "patient_07_q0",
      "generated_text": "To determine the correct course of action, let's analyze the information provided:\n\n1. The patient, Mrs. Linda Mayer, has been diagnosed with breast carcinoma.\n2. The tumor board decision from 07/12/2019 recommends the following course of action if Mrs. Mayer's BRCA testing returns negative:\n   a. If no metastasis (M0): Fast-track BRCA testing is recommended.\n   b. If BRCA testing returns negative: Proceed with a selective excision of the left breast after ultrasound-guided fine needle marking and sentinel lymph node biopsy on the left side. Additionally, perform Endopredict analysis on the surgical specimen.\n\nBased on this information, the correct course of action if Mrs. Mayer's BRCA testing returns negative is selective excision of the left breast after ultrasound-guided fine needle marking and sentinel lymph node biopsy.\n\nC"
    },
    {
      "question_id": "patient_07_q1",
      "generated_text": "To answer this question, I will follow these steps:\n\n1.  I will look for the relevant information in the provided text.\n2.  I will read the text about patient ID patient_07, which is Linda Mayer.\n3.  I will find the information about the MRI from 07/11/2019.\n\nThe text about patient ID patient_07 is in text_0. In the section labeled \"MRI from 07/11/2019\", I see the following information:\n\n[Findings:]{.underline} The overall contrast enhancement was observed bilaterally to evaluate the Grade II findings. There was low to moderate small-spotted contrast enhancement with slightly limited assessability. The contrast dynamics revealed a patchy, confluent, blurred, and elongated contrast enhancement, corresponding to the primary lesion, which measured approximately 2.4 cm on the lower left exterior.\n\nBased on this information, the size of the lesion identified in Mrs. Linda Mayer's left breast on the MRI from 07/11/2019 was 2.4 cm.\n\n**D**"
    },
    {
      "question_id": "patient_07_q2",
      "generated_text": "To answer this question, I need to find the relevant information about Mrs. Linda Mayer's diagnosis in the provided text. \n\nLooking through the texts, I see that the information about Mrs. Linda Mayer is spread across several texts (text_0, text_1, text_2, text_3, and text_4). I need to find the specific information about her left breast carcinoma diagnosis, particularly the Ki67 labeling index percentage.\n\nIn text_3, I see that under the section \"Histology: Supplemental Immunohistochemical Findings (09/04/2019):\" it mentions that the tumor biology of the invasive carcinoma demonstrates a Ki67 (MIB-1) proliferation index of 25%. However, this is for the right breast carcinoma.\n\nIn text_0, I see that under the section \"MRI from 07/11/2019:\", it mentions that the left breast carcinoma is categorized as BIRADS 6, indicating a high suspicion of malignancy. However, it does not mention the Ki67 labeling index percentage.\n\nIn text_1, I see that under the section \"Diagnosis:\", it mentions that the right breast carcinoma is ductal carcinoma in situ (DCIS) with a Ki67 labeling index of 15%. However, this is for the right breast carcinoma.\n\nIn text_2, I see that under the section \"Macroscopy:\", it mentions that the resected mammary segment from the left breast shows a maximum necrotic zone of 1.6 cm with foreign body reaction, chronic resorptive inflammation, fibrosis, and residual hemorrhage. However, it does not mention the Ki67 labeling index percentage.\n\nIn text_4, I see that under the section \"Histology: Preliminary Critical Findings Report:\", it mentions that the breast carcinoma on the left with a 1.6 cm invasive lobular carcinoma, moderately differentiated, with a B.R.E. score of 6 (3+2+1, G2). However, it does not mention the Ki67 labeling index percentage.\n\nSince I could not find the Ki67 labeling index percentage for the left breast carcinoma in the provided texts, I will make an educated guess based on the options provided.\n\n**B**"
    },
    {
      "question_id": "patient_07_q3",
      "generated_text": "To answer this question, let's first look at the provided history of Mrs. Linda Mayer (patient_07) and identify her other diagnoses.\n\nThe provided history mentions the following other diagnoses for Mrs. Mayer:\n\n- Hailey-Hailey disease\n- History of apoplexy in 2016\n- Right hip total hip replacement\n- History of left adnexectomy in 1980 due to extrauterine pregnancy\n- Tubal sterilization in 1988\n- Uterine curettage (Abrasio) in 2004\n- Hysterectomy in 2005\n- Oral thrush\n- Hypacusis\n\nNow, let's compare these diagnoses with the options given in the question:\n\nA. Hailey-Hailey disease - This is a part of Mrs. Mayer's other diagnoses.\nB. History of apoplexy in 2016 - This is also a part of her other diagnoses.\nC. Right hip total hip replacement - This is another part of her other diagnoses.\nE. History of left adnexectomy in 1980 due to extrauterine pregnancy - This is also mentioned in her history.\n\nD. Chronic obstructive pulmonary disease (COPD) - There is no mention of COPD in Mrs. Mayer's other diagnoses.\n\nBased on this comparison, the correct answer is the option that is not a part of Mrs. Mayer's other diagnoses.\n\nD."
    },
    {
      "question_id": "patient_07_q4",
      "generated_text": "According to the text, during the VAC change, a foul odor appears from the wound cavity. This suggests the presence of infection.\n\n \nB"
    },
    {
      "question_id": "patient_07_q5",
      "generated_text": "To determine which parameter indicates an abnormal finding in Linda Mayer's lab results in September 2019, let's examine the provided lab results:\n\n**Lab results upon Discharge:**\n\n  **Parameter**                    **Results**    **Reference Range**\n  -------------------------------- ------------- ---------------------\n  Sodium                           141 mEq/L     132-146 mEq/L\n  Potassium                        4.2 mEq/L     3.4-4.5 mEq/L\n  Creatinine                       0.82 mg/dL    0.50-0.90 mg/dL\n  Estimated GFR (eGFR CKD-EPI)     \\>90          \\-\n  Total Bilirubin                  0.21 mg/dL    \\< 1.20 mg/dL\n  Albumin                          4.09 g/dL     3.5-5.2 g/dL\n  CRP                              7.8 mg/L      \\< 5.0 mg/L\n  Haptoglobin                      108 mg/dL     30-200 mg/dL\n  Ferritin                         24 \u00b5g/L       13-140 \u00b5g/L\n  ALT                              24 U/L        \\< 31 U/L\n  AST                              37 U/L        \\< 35 U/L\n  Gamma-GT                         27 U/L        5-36 U/L\n  Lactate Dehydrogenase            244 U/L       135-214 U/L\n  25-OH-Vitamin D3                 91.7 nmol/L   50.0-150.0 nmol/L\n  Hemoglobin                       11.1 g/dL     12.0-15.6 g/dL\n  Hematocrit                       40.0%         35.5-45.5%\n  Red Blood Cells                  3.5 M/uL      3.9-5.2 M/uL\n  White Blood Cells                2.41 K/uL     3.90-10.50 K/uL\n  Platelets                        142 K/uL      150-370 K/uL\n  MCV                              73.0 fL       80.0-99.0 fL\n  MCH                              23.9 pg       27.0-33.5 pg\n  MCHC                             32.7 g/dL     31.5-36.0 g/dL\n  MPV                              10.7 fL       7.0-12.0 fL\n  RDW-CV                           14.8%         11.5-15.0%\n  Absolute Neutrophils             1.27 K/uL     1.50-7.70 K/uL\n  Absolute Immature Granulocytes   0.000 K/uL    \\< 0.050 K/uL\n  Absolute Lymphocytes             0.67 K/uL     1.10-4.50 K/uL\n  Absolute Monocytes               0.34 K/uL     0.10-0.90 K/uL\n  Absolute Eosinophils             0.09 K/uL     0.02-0.50 K/uL\n  Absolute Basophils               0.04 K/uL     0.00-0.20 K/uL\n  Free Hemoglobin                  5.00 mg/dL    \\< 20.00 mg/dL\n\nBased on the provided reference ranges, the parameter that indicates an abnormal finding is Hemoglobin level, which is lower than the reference range of 12.0-15.6 g/dL.\n\n**A**"
    },
    {
      "question_id": "patient_07_q6",
      "generated_text": "To answer this question, I need to find the relevant information in the provided text.\n\nFirst, I will look for the laboratory results upon discharge in September 2019 for Mrs. Linda Mayer.\n\nThe relevant text is: <text_3>\n\n**Lab results upon Discharge:**\n\n  **Parameter**                    **Results**   **Reference Range**\n  -------------------------------- ------------- ---------------------\n  Sodium                           141 mEq/L     132-146 mEq/L\n  Potassium                        4.2 mEq/L     3.4-4.5 mEq/L\n  Creatinine                       0.82 mg/dL    0.50-0.90 mg/dL\n  Estimated GFR (eGFR CKD-EPI)     \\>90          \\-\n  Total Bilirubin                  0.21 mg/dL    \\< 1.20 mg/dL\n  Albumin                          4.09 g/dL     3.5-5.2 g/dL\n  CRP                              7.8 mg/L      \\< 5.0 mg/L\n  Haptoglobin                      108 mg/dL     30-200 mg/dL\n  Ferritin                         24 \u00b5g/L       13-140 \u00b5g/L\n  ALT                              24 U/L        \\< 31 U/L\n  AST                              37 U/L        \\< 35 U/L\n  Gamma-GT                         27 U/L        5-36 U/L\n  Lactate Dehydrogenase            244 U/L       135-214 U/L\n  25-OH-Vitamin D3                 91.7 nmol/L   50.0-150.0 nmol/L\n  Hemoglobin                       11.1 g/dL     12.0-15.6 g/dL\n  Hematocrit                       40.0%         35.5-45.5%\n  Red Blood Cells                  3.5 M/uL      3.9-5.2 M/uL\n  White Blood Cells                2.41 K/uL     3.90-10.50 K/uL\n  Platelets                        142 K/uL      150-370 K/uL\n  MCV                              73.0 fL       80.0-99.0 fL\n  MCH                              23.9 pg       27.0-33.5 pg\n  MCHC                             32.7 g/dL     31.5-36.0 g/dL\n  MPV                              10.7 fL       7.0-12.0 fL\n  RDW-CV                           14.8%         11.5-15.0%\n  Absolute Neutrophils             1.27 K/uL     1.50-7.70 K/uL\n  Absolute Immature Granulocytes   0.000 K/uL    \\< 0.050 K/uL\n  Absolute Lymphocytes             0.67 K/uL     1.10-4.50 K/uL\n  Absolute Monocytes               0.34 K/uL     0.10-0.90 K/uL\n  Absolute Eosinophils             0.09 K/uL     0.02-0.50 K/uL\n  Absolute Basophils               0.04 K/uL     0.00-0.20 K/uL\n  Free Hemoglobin                  5.00 mg/dL    \\< 20.00 mg/dL\n\n\nNow, I will compare the laboratory results with the reference ranges to find the elevated parameter.\n\n- Sodium: 141 mEq/L is within the reference range (132-146 mEq/L).\n- Potassium: 4.2 mEq/L is within the reference range (3.4-4.5 mEq/L).\n- Creatinine: 0.82 mg/dL is within the reference range (0.50-0.90 mg/dL).\n- Total Bilirubin: 0.21 mg/dL is below the reference range (< 1.20 mg/dL).\n- Albumin: 4.09 g/dL is within the reference range (3.5-5.2 g/dL).\n- CRP: 7.8 mg/L is above the reference range (< 5.0 mg/L).\n- Haptoglobin: 108 mg/dL is within the reference range (30-200 mg/dL).\n- Ferritin: 24 \u00b5g/L is within the reference range (13-140 \u00b5g/L).\n- ALT: 24 U/L is within the reference range (< 31 U/L).\n- AST: 37 U/L is within the reference range (< 35 U/L).\n- Gamma-GT: 27 U/L is within the reference range (5-36 U/L).\n- Lactate Dehydrogenase: 244 U/L is within the reference range (135-214 U/L).\n- 25-OH-Vitamin D3: 91.7 nmol/L is within the reference range (50.0-150.0 nmol/L).\n- Hemoglobin: 11.1 g/dL is below the reference range (12.0-15.6 g/dL).\n- Hematocrit: 40.0% is within the reference range (35.5-45.5%).\n- Red Blood Cells: 3.5 M/uL is within the reference range (3.9-5.2 M/uL).\n- White Blood Cells: 2.41 K/uL is within the reference range (3.90-10.50 K/uL).\n- Platelets: 142 K/uL is within the reference range (150-370 K/uL).\n- MCV: 73.0 fL is within the reference range (80.0-99.0 fL).\n- MCH: 23.9 pg is within the reference range (27.0-33.5 pg).\n- MCHC: 32.7 g/dL is within the reference range (31.5-36.0 g/dL).\n- MPV: 10.7 fL is within the reference range (7.0-12.0 fL).\n- RDW-CV: 14.8% is within the reference range (11.5-15.0%).\n- Absolute Neutrophils: 1.27 K/uL is within the reference range (1.50-7.70 K/uL).\n- Absolute Immature Granulocytes: 0.000 K/uL is below the reference range (< 0.050 K/uL).\n- Absolute Lymphocytes: 0.67 K/uL is within the reference range (1.10-4.50 K/uL).\n- Absolute Monocytes: 0.34 K/uL is within the reference range (0.10-0.90 K/uL).\n- Absolute Eosinophils: 0.09 K/uL is within the reference range (0.02-0.50 K/uL).\n- Absolute Basophils: 0.04 K/uL is within the reference range (0.00-0.20 K/uL).\n- Free Hemoglobin: 5.00 mg/dL is below the reference range (< 20.00 mg/dL).\n\nBased on the comparison, the elevated parameter beyond the reference range is:\n\nCRP"
    },
    {
      "question_id": "patient_07_q7",
      "generated_text": "To determine which bacterial organism was not identified in Mrs. Linda Mayer's lesional skin swab, let's look at the text_5:\n\n\"Non-lesional Skin Smear: Normal flora.\"\n\nThis suggests that the normal flora of the skin is not indicative of any specific pathogenic bacteria. However, the lesional skin swab shows abundant Pseudomonas aeruginosa, Klebsiella oxytoca, and Serratia sp.\n\nSince the question asks which organism was NOT identified, we need to look for the option that is not listed among the identified organisms.\n\nThe options are:\nA. Pseudomonas aeruginosa\nB. MRSA\nC. Klebsiella oxytoca\nD. Serratia sp.\nE. Escherichia coli\n\nSince Pseudomonas aeruginosa, Klebsiella oxytoca, and Serratia sp. were identified, the only option that is not listed among the identified organisms is:\n\nE. Escherichia coli"
    },
    {
      "question_id": "patient_07_q8",
      "generated_text": "To determine the correct TNM classification for Mrs. Linda Mayer's right breast condition, we need to break down the information provided:\n\n1. **pT**: The 'p' indicates that the classification is for the primary tumor.\n2. **Tis (DCIS)**: DCIS stands for ductal carcinoma in situ, which means the cancer is confined to the milk ducts and has not invaded the surrounding tissue.\n3. **R0**: This indicates that the surgical margins are clear of cancer, meaning the tumor was completely removed.\n4. **G2 or G3**: The 'G' stands for grade, which is a measure of how much the tumor cells look like normal cells under a microscope. A higher grade indicates a more aggressive cancer. However, the correct grade is not specified in the provided text. The text mentions that the histology report from 09/01/2019 shows a maximum necrotic zone of 1.6 cm with foreign body reaction, chronic resorptive inflammation, fibrosis, and residual hemorrhage, and the surrounding areas show DCIS with solid and cribriform growth patterns and comedonecrosis, WHO Grade 3, Nuclear Grade 3. This indicates that the correct grade is G3.\n\nNow, considering the options provided:\n\nA. pTis (DCIS), R0, G2 - This option is incorrect because the grade mentioned in the histology report is G3, not G2.\n\nB. pTis (DCIS), R0, G3 - This option matches the information provided in the histology report from 09/01/2019.\n\nC. pN1a, R0, G3 - This option is incorrect because it mentions pN1a, which refers to the lymph node status, but the information provided focuses on the primary tumor and its characteristics.\n\nD. pN1b, R0, G2 - This option is incorrect because it mentions pN1b, which is not mentioned in the provided text, and the grade mentioned is G3, not G2.\n\nE. pT1c, R0, G3 - This option is incorrect because it mentions pT1c, which refers to an invasive tumor, but the information provided indicates that the cancer is in situ (DCIS).\n\nTherefore, the correct option is:\n\nB."
    },
    {
      "question_id": "patient_07_q9",
      "generated_text": "To answer this question, let's analyze the options given in the context of the histopathological examination of the skin spindle from Mrs. Linda Mayer's mammary right scar.\n\nA. Multilayered keratinizing squamous epithelium - This is a normal finding in skin tissue, but it's not directly related to the histopathological examination of the skin spindle from the mammary right scar in the context of breast carcinoma.\n\nB. Fibrosis and chronic inflammation - These are mentioned in the histopathological report as findings in the skin spindle from the mammary right scar.\n\nD. Mononuclear-dominated inflammatory infiltrates - This is also mentioned in the histopathological report as a finding in the skin spindle from the mammary right scar.\n\nE. Proliferation of collagenous connective tissue - This is another finding mentioned in the histopathological report.\n\nC. Atypical epithelial infiltrates - This option is not mentioned in the histopathological report as a finding in the skin spindle from the mammary right scar.\n\nGiven the information provided, the correct answer is the option that mentions something not found in the histopathological examination.\n\nC"
    },
    {
      "question_id": "patient_07_q10",
      "generated_text": "To answer this question, let's first identify the medication regimen for Linda Mayer in July 2019 and January 2021.\n\nIn July 2019, the medication regimen is not fully listed, but we can see the following medications:\n- Acetaminophen (500 mg 1-1-1)\n- Prednisolone (5 mg 1.5-0-0-0-0-0)\n- Tramadol/Naloxone (50/4 mg 1-0-1)\n\nIn January 2021, the medication regimen is listed as follows:\n- Prednisolone (5 mg 1.5-0-0-0-0-0)\n- Acetaminophen (500 mg 1-1-1)\n- Naloxone (8.8 mg 1-0-1)\n- Eszopiclone (7.5 mg 0-0-1-0)\n\nComparing the two medication regimens, we can see that Tramadol/Naloxone (Ultram) was used in July 2019 but not in January 2021."
    },
    {
      "question_id": "patient_07_q11",
      "generated_text": "To answer this question, we need to look at the medication regimens provided in the texts for Mrs. Mayer in 2019 and 2021.\n\nIn 2019, the medication list includes:\n\n* Aspirin (100mg, 0-1-0-0-0-0)\n* Simvastatin (40mg, 0-0-0-0-1)\n* Pantoprazole (45.1mg, 1-0-0-0-0)\n* Acitretin (25mg, 1-0-0-0-0)\n* Prednisolone (5mg, 1.5-0-0-0-0-0)\n* Tetrabenazine (111mg, 0.25-0.25-0.25-0.25-0.25-0.25)\n* Letrozole (2.5mg, 0-0-1-0)\n* Risedronate Sodium (35mg, 1-0-0-0-0)\n* Acetaminophen (500mg, 0-1-0-1)\n* Naloxone (8.8mg, 1-0-1-0)\n* Eszopiclone (7.5mg, 0-0-1-0)\n\nIn 2021, the medication list includes:\n\n* Aspirin (100mg, 0-1-0)\n* Simvastatin (40mg, 0-0-0-0-1)\n* Pantoprazole (40mg, 1-0-0)\n* Acitretin (25mg, 1-0-0)\n* Prednisolone (5mg, 2-0-0)\n* Tetrabenazine (111mg, 0.25-0.25-0.25-0.25-0.25-0.25)\n* Letrozole (2.5mg, 0-0-1-0)\n* Risedronate Sodium (35mg, 1-0-0)\n* Acetaminophen (500mg, 0-1-0-1)\n* Naloxone (8.8mg, 1-0-1-0)\n* Eszopiclone (7.5mg, 0-0-1-0)\n\nComparing the two lists, we can see that the dosing frequency of Prednisolone was changed from 1.5-0-0-0-0-0-0 to 2-0-0 in 2021. This reduction in dosing frequency likely indicates a clinical improvement, as the patient may no longer need to take Prednisolone as frequently.\n\n**D**"
    },
    {
      "question_id": "patient_07_q12",
      "generated_text": "To determine which color corresponded to the caudal margin, we need to refer to the text_4 section where the description of the left subcutaneous mastectomy is provided.\n\nIn the text, it is mentioned that the specimen was marked with dual filament-labeled subcutaneous mastectomy specimen with assumed suture markings: Blue (Ventral) and Green (Cranial). This indicates that the green filament corresponds to the cranial margin, and the blue filament corresponds to the ventral margin.\n\nSince the caudal margin is the opposite of the cranial margin, the caudal margin would correspond to the **yellow** filament.\n\n**D**"
    },
    {
      "question_id": "patient_07_q13",
      "generated_text": "To determine how long Mrs. Linda Mayer had been postmenopausal at the time of her diagnosis, we need to know her menopause age and her age at the time of diagnosis.\n\nSince her birthday is 1948-12-01, and her diagnosis is 2019, we can calculate her age at the time of diagnosis as follows:\n\n2019 - 1948 = 71 years\n\nHowever, we don't know her menopause age. If we assume that menopause typically occurs around age 50, then:\n\n71 - 50 = 21 years\n\nHowever, this is not among the options, so let's assume menopause occurred at a different age. If menopause occurred at age 40:\n\n71 - 40 = 31 years\n\nStill not among the options. If menopause occurred at age 45:\n\n71 - 45 = 26 years\n\nStill not among the options. If menopause occurred at age 55:\n\n71 - 55 = 16 years\n\nStill not among the options. If menopause occurred at age 50 is too low, and menopause at 55 is too low, then it's likely that menopause occurred at an age close to 50 but higher, such as 52.\n\n71 - 52 = 19 years\n\nStill not among the options. If menopause occurred at age 53:\n\n71 - 53 = 18 years\n\nThis is among the options. Therefore, the correct answer is:\n\nE"
    },
    {
      "question_id": "patient_07_q14",
      "generated_text": "To determine the correct answer, I will go through the provided texts and look for information about Mrs. Linda Mayer's allergies.\n\nFrom text_0, under the section \"Current Medication:\", I see a list of medications Mrs. Mayer is currently taking. However, I do not see any information about allergies.\n\nFrom text_1, under the section \"Allergies:\", I see that Mrs. Mayer has an allergy to \"Hay fever\".\n\nFrom text_4, under the section \"Allergies:\", I see that Mrs. Mayer has an allergy to \"Hay fever\".\n\nTherefore, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_07_q15",
      "generated_text": "To determine the correct answer, I will analyze the provided text.\n\nThe patient's name is Linda Mayer, and the question asks about the date of the tumor board decision. \n\nLooking through the text, I find the following relevant information:\n\nIn text_0, there is a section titled \"Tumor board decision from 07/13/2019\" which implies that the tumor board decision was made on 07/13/2019.\n\nIn text_1, there is a section titled \"Tumor Board Decision:\" which mentions \"Tumor board decision from 07/13/2019\". This further confirms that the tumor board decision was made on 07/13/2019.\n\nTherefore, the correct answer is A.\n\nA."
    },
    {
      "question_id": "patient_07_q16",
      "generated_text": "To answer this question, I will refer to the provided text. The text mentions Mrs. Mayer's surgery report, which includes the following information about the tumor resection margins: \"Ventral 0.15 cm, caudal 0.2 cm, dorsal 0.4 cm, and the remaining sedimentation margins more than 0.5 cm.\"\n\nBased on this information, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_07_q17",
      "generated_text": "To answer this question, I will follow these steps:\n\n1. Identify the patient: ID patient_07, Name: Linda Mayer, Birthday: 1948-12-01 00:00:00, Diagnosis: Breast carcinoma\n\n2. Search for the patient's discharge information in the provided texts.\n3. Find the relevant lab result: platelet count at discharge.\n\nAfter searching through the provided texts, I found the relevant information in text_4:\n\n**Lab results upon Discharge:**\n\n  **Parameter**                    **Results**   **Reference Range**\n  -------------------------------- ------------- ---------------------\n  Platelets                        142 K/\u00b5L       150-370 K/\u00b5L\n\nTherefore, Mrs. Mayer's platelet count at discharge was 142 K/\u00b5L.\n\n**C**"
    },
    {
      "question_id": "patient_07_q18",
      "generated_text": "To find the answer, I will follow these steps:\n\n1.  Look for the relevant text related to Mrs. Mayer's treatment.\n2.  Identify the specific information about the prednicarbate cream used in her treatment.\n3.  Determine the concentration of the prednicarbate cream used.\n\nThe relevant text is from text_6:\n\n**Medical History:** Mrs. Linda Mayer was referred to our hospital for the management of Hailey-Hailey disease after assessment in our outpatient clinic. She reported a worsening of painful skin erosions on her neck and inner thighs over a span of approximately 3 weeks. \n\n**Therapy and Progression:** Mrs. Mayer was admitted on 01/01/2021 as an inpatient for a refractory exacerbation of previously diagnosed Hailey-Hailey disease. On admission, both bacteriological and mycological smears were conducted, which indicated abundant levels of Pseudomonas aeruginosa, Klebsiella oxytoca, and Serratia sp. Lab tests showed a CRP level of 2.83 mg/dL and a leukocyte count of 8.8 G/L.\n\nInitial topical therapy consisted of Zinc oxide ointment, Clotrimazole paste, and Triamcinolone Acetonide shake lotion. Treatment was modified on 01/04/2021 to include Clotrimazole (Lotrimin) paste in the mornings and methylprednisolone emulsion in the evenings. Starting on 01/08, eosin aqueous solution was introduced for application on the thighs, serving antiseptic and drying purposes. A hydrophilic prednicarbate cream at 0.25% concentration, combined with octenidine at 0.1%, was applied to the neck and thighs twice daily, also starting on 01/08.\n\nFor the question, the relevant information is: A hydrophilic prednicarbate cream at 0.25% concentration, combined with octenidine at 0.1%, was applied to the neck and thighs twice daily, also starting on 01/08.\n\nThe concentration of the prednicarbate cream used in Mrs. Mayer's treatment starting on 01/08/2021 is 0.25%.\n\n**D**"
    },
    {
      "question_id": "patient_07_q19",
      "generated_text": "To determine the chronological sequence of the radiological imaging procedures that Mrs. Mayer underwent, let's analyze the information provided in the text.\n\n1.  The first radiological imaging procedure mentioned is Mammography and Tomosynthesis, which is indicated for the initial examination of the breast.\n2.  Following this, a Breast MRI was conducted to further evaluate the findings.\n3.  The next imaging procedure mentioned is CT chest and abdomen, which was performed to assess the liver and other abdominal organs.\n4.  Finally, Digital Mammography was conducted for further evaluation.\n\nTherefore, the chronological sequence of the radiological imaging procedures that Mrs. Mayer underwent is: Mammography and Tomosynthesis, Breast MRI, CT chest and abdomen, and Digital Mammography.\n\n**E**"
    },
    {
      "question_id": "patient_08_q0",
      "generated_text": "To determine which vertebrae were affected by osteoporotic sintering in Laura Miller's case, I will follow these steps:\n\n1. Review the provided text for information about Laura Miller's diagnosis and treatment.\n2. Find the relevant section about Laura Miller's diagnosis and treatment.\n3. Identify the specific vertebrae mentioned in the text as being affected by osteoporotic sintering.\n\nThe relevant section is in text_0, under the section \"Thoracic Spine 2 levels from 05/22/2020, Lumbar spine in 2 planes from 05/22/2020\". \n\nAccording to the text, \"Multiple thoracic vertebral bodies exhibit decreased height, most notably at the central region where a measurement of approximately 17 mm suggests significant height loss and potential acute fracture. Additionally, there are endplate impressions in individual vertebrae of the lower thoracic spine.\"\n\nHowever, this text does not specify which thoracic vertebrae are affected. The text does mention that there is a suspected hemangioma in a vertebral body of the lower thoracic spine, but it does not specify which vertebrae are affected by osteoporotic sintering.\n\nThe text also mentions that \"In a presumed five-segment lumbar spine, the L1 vertebra shows a subtle reduction in height with a questionable endplate impression.\"\n\nTherefore, based on the information provided, I can only be sure about the lumbar vertebra that is affected by osteoporotic sintering, which is L1.\n\nSince I am not sure about the thoracic vertebrae, I will make a guess based on the information provided. The text mentions that there are endplate impressions in individual vertebrae of the lower thoracic spine, but it does not specify which vertebrae. However, it does mention that there is a suspected hemangioma in a vertebral body of the lower thoracic spine. Based on this information, I will guess that the thoracic vertebrae affected are Th8.\n\nTherefore, my answer is: A"
    },
    {
      "question_id": "patient_08_q1",
      "generated_text": "To answer this question, I will follow these steps:\n\n1.  Identify the patient: Laura Miller\n2.  Identify the relevant information: CT of the thoracic spine\n3.  Find the relevant text: <text_0>, <text_1>, <text_2>, <text_3>, <text_4>, <text_5>, <text_6>, <text_7>\n\nThe relevant text is in <text_0> under the section \"Thoracic Spine 2 levels from 05/22/2020, Lumbar spine in 2 planes from 05/22/2020:\". The text states: \"Multiple thoracic vertebral bodies exhibit decreased height, most notably at the central region where a measurement of approximately 17 mm suggests significant height loss and potential acute fracture.\"\n\nHowever, I am looking for an \"additional finding.\" The relevant text also states: \"Aortic sclerosis is present, along with degenerative changes throughout the thoracic vertebrae. The osseous structure presents osteoporotic features.\"\n\nTherefore, I will choose the option that corresponds to aortic sclerosis.\n\n \nE"
    },
    {
      "question_id": "patient_08_q2",
      "generated_text": "To answer this question, I need to find the information about Laura Miller's medication in the provided texts.\n\n1. I will search for the text that contains information about Laura Miller.\n2. I will look for the specific information about her medication in May 2020.\n3. I will identify the medication used for analgesia.\n\nAfter searching the texts, I found the information about Laura Miller's medication in text_0.\n\nIn text_0, under the section \"Other Findings:\", it is mentioned that \"Analgesia as needed using Acetaminophen 500mg 1-1-1 under gastric protection.\"\n\nSo, the correct answer is:\n\n**B**"
    },
    {
      "question_id": "patient_08_q3",
      "generated_text": "To answer this question, we need to refer to the text where the classification of Laura Miller's esophageal varices is mentioned. \n\nThe text states: \"Grade III esophageal varices present without definitive high-risk stigmata. Varices also noted at the gastroesophageal junction, classified as GOV 1 according to Sarin's classification.\"\n\nBased on this information, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_08_q4",
      "generated_text": "To answer this question, let's break it down step by step:\n\n1. We are looking for the imaging performed on Laura Miller on a specific date, 06/13/2020.\n2. The options given are different types of imaging, including MRI, CT, and X-ray.\n3. We need to find the option that matches the imaging performed on Laura Miller on the specified date.\n\nAfter reviewing the text, I found the relevant information:\n\n\"...MR Liver plain + contast agent from 06/06/2020...\"\n\nThis indicates that an MRI of the liver was performed on 06/06/2020, but not on 06/13/2020.\n\nHowever, looking at the options again, I found another relevant information:\n\n\"...Spine-whole: 2 planes from 06/13/2020...\"\n\nThis indicates that a spine-whole imaging in 2 planes was performed on 06/13/2020.\n\nSo, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_08_q5",
      "generated_text": "To determine the date of the thoracic spine kyphoplasty, I will look for the relevant information in the provided texts.\n\nIn text_1, I find that a holospinal MRI was performed on 06/04/2020, but there is no mention of a kyphoplasty on this date.\n\nIn text_2, I find that a MRI of the liver was performed on 06/06/2020, but there is no mention of a kyphoplasty on this date.\n\nIn text_3, I find that a CT Chest/Abdomen/Pelvis with contrast agent was performed on 06/18/2020, but there is no mention of a kyphoplasty on this date.\n\nIn text_4, I find that a MRI of the liver was performed on 06/19/2020, but there is no mention of a kyphoplasty on this date.\n\nHowever, in text_1, I also find that a holospinal MRI was performed on 06/13/2020, and in text_3, I find that a CT Chest/Abdomen/Pelvis with contrast agent was performed on 06/18/2020, but there is a mention of a kyphoplasty in text_1 and text_3.\n\nIn text_1, I find that a DSA coeliac-mesenteric was performed on 08/13/2020, which involved a SIRT simulation, but there is no mention of a kyphoplasty on this date.\n\nHowever, in text_3, I find that a CT Chest/Abdomen/Pelvis with contrast agent was performed on 06/18/2020, but there is a mention of a kyphoplasty on 06/14/2020 in text_1.\n\nTherefore, I will look for the relevant information in text_1.\n\nIn text_1, I find that a DSA coeliac-mesenteric was performed on 08/13/2020, which involved a SIRT simulation, but there is a mention of a kyphoplasty on 06/14/2020.\n\nThe answer is B."
    },
    {
      "question_id": "patient_08_q6",
      "generated_text": "To determine when the total spine MRI plain was conducted for Laura Miller, I'll review the provided text.\n\nThe text mentions several MRI dates, but I'll look for the one that specifically mentions the total spine MRI plain.\n\nThe text mentions the following MRI dates:\n\n- **06/04/2020**: This is mentioned as the date for a MRI total spine plain, but the technique and findings are described, not the specific date of the procedure.\n- **06/06/2020**: This is mentioned as the date for a MRI liver plain with contrast agent, not the total spine MRI plain.\n- **06/13/2020**: This is mentioned as the date for a spine-whole examination in 2 planes, but it's not the date for the total spine MRI plain.\n- **06/18/2020**: This is mentioned as the date for a CT Chest/Abdomen/Pelvis with contrast agent, not the total spine MRI plain.\n- **06/19/2020**: This is mentioned as the date for a histology report, not the total spine MRI plain.\n\nHowever, I found the date **06/04/2020** mentioned as the date for a MRI total spine plain with a specific technique and findings, which is the closest match to the question's requirements.\n\nSo, I'm going to guess **A**."
    },
    {
      "question_id": "patient_08_q7",
      "generated_text": "To find the correct answer, I will analyze the given reports for patient Laura Miller.\n\nThe report from text_0 mentions that Laura Miller was admitted on 05/27/2020 and discharged on 06/22/2020.\n\nThe report from text_1 mentions that Laura Miller was in our inpatient treatment from 05/27/2020 to 06/22/2020.\n\nThe report from text_2 mentions that Laura Miller was under our inpatient care from 08/21/2020 to 08/23/2020.\n\nThe report from text_3 mentions that Laura Miller was under our inpatient care from 09/18/2020 to 09/20/2020.\n\nThe report from text_4 is not relevant to the question as it is about a different patient.\n\nSince the question asks for Laura Miller's last inpatient treatment, I will look for the latest date mentioned in the relevant reports.\n\nThe report from text_3 mentions that Laura Miller was under our inpatient care from 09/18/2020 to 09/20/2020, which is the latest date mentioned in the relevant reports.\n\n\n \nE"
    },
    {
      "question_id": "patient_08_q8",
      "generated_text": "To determine the correct answer, let's refer to the relevant text (text_1). The MR Liver plain + contrast agent report from 06/06/2020 mentions two lesions:\n\n1) [Lesion 1]{.underline}: Size of the lesion 41 mm\n2) [Lesion 2]{.underline}: Size of the lesion 104 mm\n\nSince we are looking for the size of the largest lesion, we should select the larger of the two sizes mentioned.\n\nThe largest lesion found in Laura Miller's liver was 104 mm, which corresponds to option A."
    },
    {
      "question_id": "patient_08_q9",
      "generated_text": "To answer this question, let's analyze the information provided about Laura Miller's condition and the liver board decision on 08/21/2020.\n\n1. The patient was diagnosed with liver cirrhosis due to ethyl toxicity.\n2. In June 2020, the patient was diagnosed with multifocal HCC (Hepatocellular Carcinoma).\n3. The liver board decision on 06/13/20 recommended a repeat variceal screening on 08/28/20, depending on the findings.\n4. The patient presented electively for gastroscopy for variceal screening with continuation of banding therapy due to esophageal variceal bleeding on 08/21/2020.\n\nConsidering these points, the significant change observed in Laura Miller's condition leading to the liver board decision on 08/21/2020 is the progression of multifocal HCC, which led to the recommendation for a repeat variceal screening and further discussion of potential treatment options.\n\n**B**"
    },
    {
      "question_id": "patient_08_q10",
      "generated_text": "To answer this question, we need to look at the text provided for patient Laura Miller, specifically the Esophagogastroduodenoscopy performed on 08/21/2020. \n\nThe text states: \"EGD on 08/21/2020: \n**Findings:** \n**Esophagus**: Unobstructed intubation of the esophagus under direct vision. Multiple variceal cords and scarring changes due to banding were observed in the lower half of the esophagus. Z-line at 35 cm diaphragmatic passage at 39 cm. Two variceal cords extend along the small curve into the stomach, two of the varices show alarm signs (red spots). 4 rubber band ligations were performed.\"\n\nBased on this information, the significant finding in the Esophagogastroduodenoscopy performed on 08/21/2020 is that there were esophageal varices with alarm signs.\n\n**E**"
    },
    {
      "question_id": "patient_08_q11",
      "generated_text": "To determine the correct answer, I will look for the relevant information in the provided text.\n\nThe text mentions several CT scans performed on Laura Miller, but I need to find the one that matches the description \"CT Chest/Abdomen/Pelvis with contrast agent\". \n\nAfter reviewing the text, I found the relevant information in the section <text_1> under the title **Dear colleague,**. The relevant text is:\n\n\"**CT Chest/Abdomen/Pelvis with contrast agent from 06/18/2020:**\n\n**Technique**: Multislice spiral CT of the chest, abdomen, and pelvis was performed post-bolus intravenous injection of 120 ml of Imeron 400. Imaging conducted in arterial, portal venous, and venous phases. Oral contrast agent administered with Micropaque 1:7 in water and Gastrolux 1:33 in water. Thin-slice reconstructions and secondary coronal and sagittal reformats were performed.\"\n\nBased on this information, the CT scan of the chest/abdomen/pelvis with contrast agent was performed on June 18th, 2020.\n\n**C**"
    },
    {
      "question_id": "patient_08_q12",
      "generated_text": "To determine the correct answer, let's analyze the information provided in the text.\n\nThe patient, Laura Miller, underwent various medical procedures and examinations between 05/20/2020 and 09/20/2020. The options given are:\n\nA. MRI of the liver\nB. Ultrasound of the upper abdomen\nC. Esophagogastroduodenoscopy with banding therapy\nD. CT Chest/Abdomen/Pelvis with contrast\nE. Kyphoplasty of thoracic vertebra 8\n\nOn 08/21/2020, the procedure mentioned is an Esophagogastroduodenoscopy with banding therapy, as described in the text:\n\n\"On 08/21/2020, an uncomplicated gastroscopy was performed, including the application of 4 rubber band ligations for residual esophageal varices.\"\n\nThe correct answer is C."
    },
    {
      "question_id": "patient_08_q13",
      "generated_text": "To determine when the MR Liver plain + contrast agent examination was conducted for Laura Miller, I will review the provided text and look for the relevant information.\n\nThe text mentions the following MR Liver plain + contrast agent examinations:\n\n- On 06/06/2020, an MR examination was conducted, and the findings are described.\n\nSince the question asks for the date of the MR Liver plain + contrast agent examination, I will choose the date mentioned in the text as the answer.\n\n06/06/2020 is the date mentioned in the text, which corresponds to option B.\n\n**B**"
    },
    {
      "question_id": "patient_08_q14",
      "generated_text": "To determine the correct date of the ultrasound of the abdomen showing liver cirrhosis for Laura Miller, let's look at the provided text and identify the relevant information:\n\nThe text mentions that Laura Miller was diagnosed with liver cirrhosis and underwent various medical procedures and examinations between May and June 2020. The ultrasound of the abdomen is mentioned in the following text:\n\n\"Ultrasound of the upper abdomen on 05/27/2020: Limited assessable due to meteorism. Liver: Liver dimensions are within normal limits, measuring 15.9 cm in the craniocaudal axis. Echotexture demonstrates inhomogeneous granularity. There is hepatic margin convexity and nodular surface appearance. Rarification of hepatic veins. Segment III reveals two hypoechoic lesions measuring 3 cm and 1 cm in diameter. Portal vein demonstrates orthograde flow with a maximum velocity of 17 cm/s.\"\n\nBased on this information, the ultrasound of the abdomen showing liver cirrhosis was performed on 05/27/2020.\n\n**E**"
    },
    {
      "question_id": "patient_08_q15",
      "generated_text": "To determine Mrs. Miller's condition upon admission for inpatient care from 09/18/2020 to 09/20/2020, let's break down the information provided in the text.\n\n1. The patient, Laura Miller, was admitted from 09/18/2020 to 09/20/2020.\n2. The diagnosis mentioned is multifocal HCC segment with portal vein invasion, BCLC C, and a history of decompensated liver cirrhosis.\n3. The patient had a history of esophageal varices and had undergone banding therapy.\n4. The patient had a history of anemia requiring transfusion.\n5. The patient had a history of arterial hypertension.\n6. The patient had a history of osteoporotic thoracic vertebra 8 fracture.\n\nBased on the information provided, the correct answer is **E**. All of the above."
    },
    {
      "question_id": "patient_08_q16",
      "generated_text": "To answer this question, let's analyze the provided text and the CT scan findings mentioned for patient Laura Miller.\n\n1. The text mentions that a CT scan was performed on 06/18/2020.\n2. The CT scan was done with a contrast agent and included imaging of the chest, abdomen, and pelvis.\n3. The findings from the CT scan are mentioned as follows: \"Bilateral minor pleural effusions with adjacent atelectasis, more pronounced on the right and extending into the interlobar region.\"\n\nBased on this information, we can identify the correct answer.\n\n \nE"
    },
    {
      "question_id": "patient_08_q17",
      "generated_text": "To determine Mrs. Miller's nutritional status as of the consultation on 06/08/2020, let's consider the information provided:\n\n1. Mrs. Miller's albumin level was 2.6, which is below the normal range (typically considered normal between 3.5 and 5.2 g/dL). Low albumin levels can indicate malnutrition or liver disease, among other conditions.\n2. Mrs. Miller reported that she was a \"bad eater,\" suggesting that she may not be consuming a balanced diet.\n3. She mentioned that she eats less due to numerous medication intake, which can affect her nutritional status.\n\nConsidering these points, the most likely answer is:\n\nC. Protein malnutrition"
    },
    {
      "question_id": "patient_08_q18",
      "generated_text": "To determine which medication was not ascertainably part of Mrs. Miller's regimen, let's review the provided text.\n\nText_0 mentions the following medications for Mrs. Miller:\n\n- Blood pressure medication\n- Osteoporosis medication\n- Acetaminophen (pain relief medication)\n- Prednisolone (which can be used for various conditions, including inflammation and pain)\n\nHowever, there is no mention of anticoagulation medication or antibiotics in the provided text.\n\nTherefore, based on the information given, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_08_q19",
      "generated_text": "Let's break down the sequence of radiology imaging examinations that Mrs. Miller underwent based on the provided texts:\n\n1. Initial examination: X-ray thoracic and lumbar spine (05/22/2020)\n2. Next examination: CT thoracic spine (05/22/2020)\n3. Then, an abdominal ultrasound was performed (05/27/2020)\n4. After that, a Chest X-ray was done (05/28/2020)\n5. Another abdominal ultrasound was performed (05/29/2020)\n6. MRI total spine was done (06/04/2020)\n7. MRI liver plain was performed (06/06/2020)\n8. Esophagogastroduodenoscopy was conducted (06/11/2020)\n9. Spine whole in 2 planes was imaged (06/13/2020)\n10. CT Chest/Abdomen/Pelvis was done (06/18/2020)\n\nConsidering the above steps, the correct sequence of radiology imaging examinations is:\n\nInitial X-ray of thoracic and lumbar spine < CT scan of thoracic spine < Abdominal ultrasound - initial examination < Radiographic Chest X-ray < Abdominal ultrasound - follow-up  < Plain MRI of liver < Complete Spine imaging in 2 planes < Total spine MRI < Comprehensive CT of Chest/Abdomen/Pelvis\n\nSo, the correct answer is: **D**"
    },
    {
      "question_id": "patient_09_q0",
      "generated_text": "To answer this question, let's follow the steps:\n\n1. The question is asking about the size of the echo-depleted mass in Mr. Wells' liver Segment IV.\n2. We need to find the relevant information in the text related to this question.\n3. The text mentions the ultrasound examination on 07/26/2019.\n4. In the text, under the date 07/26/2019, there is a description of the ultrasound examination, which includes the finding of an echo-depleted mass in Segment IV.\n5. The size of the mass is described as approximately 8.3 x 6 cm.\n\nTherefore, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_09_q1",
      "generated_text": "To determine the correct answer, let's analyze the given information step by step:\n\n1. The question mentions an MRI of the liver taken on 07/26/2019 for Mr. Wells.\n2. The question asks about the characteristics of the hepatic masses noted on the MRI.\n3. We need to find the correct option that describes the characteristics of the hepatic masses.\n\nLooking at the provided texts, the MRI of the liver plain + contrast agent from 07/26/2019 mentions the following:\n\n- The hepatic masses in liver segments 4, 7, and 8 demonstrate T2 hyperintensity, marked diffusion restriction, arterial phase enhancement, and venous phase washout.\n\nBased on this information, the correct answer is:\n\n**B**"
    },
    {
      "question_id": "patient_09_q2",
      "generated_text": "To answer this question, I will follow the steps below:\n\n1.  Find the relevant information in the text about the colonoscopy performed on Mr. Wells on 07/28/2019.\n2.  Identify what was found and removed from Mr. Wells' sigmoid colon during the colonoscopy.\n3.  Match the information to the possible answers.\n\nThe relevant text is:\n\n**Colonoscopy from 07/28/2019**\n\n**Findings:**\n\n**Colon:** Some residual fluid contamination is noted in the sigmoid (Boston Bowel Preparation Scale [BBPS] 8). There is pronounced sigmoid diverticulosis, along with multiple colonic diverticula. A 4mm polyp in the lower sigma (Paris IIa, NICE 1) is observed and ablated with a cold snare, with hemoclip application for bleeding prophylaxis. Other mucosal findings appear inconspicuous, with normal vascular markings. There is no indication of inflammatory or malignant processes.\n\n**Maximum Insight:** Terminal ileum.\n\n**Anus:** Inspection of the anal region reveals no pathological findings. Palpation is inconspicuous, and the mucosa is smooth and displaceable, with no resistance and no blood on the glove.\n\n**Assessment:** Polypectomy was performed for sigmoid diverticulosis and a colonic diverticulum, with histology revealing minimally hyperplastic colorectal mucosa and no evidence of malignancy.\n\nBased on the information, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_09_q3",
      "generated_text": "To determine the liver fibrosis stage in Mr. Wells, we need to look for information related to liver fibrosis in the provided reports. \n\nThe report on 08/24/2019 mentions that Mr. Wells had a history of elevated alcohol consumption, specifically 3-4 beers per day, which is likely contributing to his liver fibrosis. However, it does not provide a specific liver fibrosis stage.\n\nTherefore, based on the information given, the correct answer is:\n\nE. Not specified"
    },
    {
      "question_id": "patient_09_q4",
      "generated_text": "To answer this question, let's go through the information provided in the texts about Mr. Wells.\n\nMr. Wells was treated with Atezolizumab/Bevacizumab for his hepatocellular carcinoma (HCC). We are looking for complications he did not experience after this treatment.\n\nText 2 mentions that Mr. Wells experienced \"significant side effects, including oral burning, appetite and weight loss, low blood pressure, and worsening pulmonary status\" after re-administration of Atezolizumab/Bevacizumab. \n\nText 5 mentions that Mr. Wells experienced \"severe pneumonic sepsis\" after the administration of Atezolizumab/Bevacizumab.\n\nText 3 mentions that Mr. Wells experienced \"transient worsening of lung function with steroid requirement after Atezolizumab/Bevacizumab administrations\" but does not specifically mention high blood pressure or elevated transaminases as complications.\n\nHowever, it is worth noting that text 1 does mention \"transaminase elevation (up to 4x ULN)\" but it is not explicitly stated that this was a complication of Atezolizumab/Bevacizumab, but rather a reason for a treatment pause.\n\nConsidering the information provided, Mr. Wells experienced oral burning, worsening pulmonary status, and severe pneumonic sepsis as complications of Atezolizumab/Bevacizumab, but there is no clear evidence that he experienced high blood pressure or elevated transaminases as direct complications of the treatment.\n\nHowever, based on the information given, I will make a guess that the best answer is A."
    },
    {
      "question_id": "patient_09_q5",
      "generated_text": "To determine the correct answer, let's analyze the information provided:\n\n1. We are looking for the date when Mr. Wells was diagnosed with Community-Acquired Pneumonia (CAP).\n2. We have multiple text blocks (text_0 to text_7) that contain information about Mr. Wells' medical history.\n3. The key phrase to look for is \"Community-Acquired Pneumonia (CAP)\".\n4. After reviewing the text blocks, we find that text_5 mentions \"Community-Acquired Pneumonia (CAP)\" in the following sentence: \"Mr. Wells complained about progressively worsening respiratory symptoms, which included shortness of breath, productive cough with yellow-green sputum, pleuritic chest pain, fever, and chills, spanning a period of five days.\"\n\n5. The sentence is located in the following text block: text_5.\n\n6. The text block text_5 indicates that Mr. Wells was in the hospital from 02/04/2021 to 02/12/2021, which suggests that the diagnosis of Community-Acquired Pneumonia (CAP) occurred during this period.\n\n7. Based on the information provided, the most likely date for the diagnosis of Community-Acquired Pneumonia (CAP) is during the hospital stay from 02/04/2021 to 02/12/2021.\n\nTherefore, the correct answer is:\n\nD. 04/02/2021"
    },
    {
      "question_id": "patient_09_q6",
      "generated_text": "To determine the causative pathogen for Mr. Wells' pneumogenic sepsis, we need to look for information about the pathogen detected in the patient's sputum culture.\n\nAccording to the text, on 06/11/2020, an esophagogastroduodenoscopy was performed, and a sputum culture was collected. The culture revealed Streptococcus pneumoniae as the causative pathogen.\n\nSo, the correct answer is: **B**"
    },
    {
      "question_id": "patient_09_q7",
      "generated_text": "To answer this question, let's break it down step by step:\n\n1. We are looking for information about the MRI Liver on 11/20/2020.\n2. The patient's name is Paul Wells, and the relevant information is about his hepatic lesions.\n3. We need to find the correct statement about the MRI findings.\n\nBased on the provided text, the MRI Liver on 11/20/2020 is described in the following text:\n\n\"**MRI Liver (plain + contrast agent) on 11/20/2020 09:01 AM.**\n\n-   Imaging revealed stable findings in the liver. The previously identified HCC lesions in segments IV, VII/VIII, including their size and characteristics, remained largely unchanged. There was no evidence of new lesions or metastases. Detailed MRI imaging provided valuable insight into the nature of the lesions, their vascularity, and possible effects on adjacent structures.\"\n\nTherefore, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_09_q8",
      "generated_text": "To answer this question, I will follow these steps:\n\n1.  I will look for information about Mr. Wells' COPD severity level as of 11/20/2020 in the provided text.\n2.  I will identify the relevant sentence or phrase that mentions the COPD severity level.\n\nFrom the provided text, I found the relevant information in <text_4>. In the section titled **Pulmonary Function Testing**, it is mentioned that \"Pulmonary function tests confirmed his current severity score of Gold III, indicating advanced COPD.\"\n\nTherefore, based on the provided information, the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_09_q9",
      "generated_text": "To determine the correct answer, I will analyze the information provided in the text related to Mr. Wells' condition.\n\nThe text mentions that Mr. Wells has a diagnosis of Hepatocellular carcinoma (HCC), which is a type of liver cancer. However, it also mentions that he has a condition that necessitates home oxygen therapy.\n\nUpon reviewing the text, I find that Mr. Wells has a history of COPD (Chronic Obstructive Pulmonary Disease) with a current severity level of Gold III, and pulmonary emphysema, which are conditions that affect the lungs and can lead to breathing difficulties.\n\nConsidering these conditions, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_09_q10",
      "generated_text": "To determine Mr. Wells' GFR upon discharge, we need to look for the relevant lab result in the provided text.\n\n1. We need to find the text related to Mr. Wells' patient ID (patient_09).\n2. We find the text and search for lab results upon discharge.\n3. The lab results upon discharge are:\n\n  **Parameter**                    **Results**   **Reference Range**\n  -------------------------------- ------------- ---------------------\n  Sodium (Na)                   144 mEq/L     134-145 mEq/L\n  Potassium (K)                 3.7 mEq/L     3.4-5.2 mEq/L\n  Calcium (Ca)                  2.37 mEq/L    2.15-2.65 mEq/L\n  Chloride (Cl)                 106 mEq/L     95-112 mEq/L\n  Inorganic Phosphate (PO4)     0.93 mEq/L    0.8-1.5 mEq/L\n  Transferrin Saturation        20 %          16-45 %\n  Magnesium                     0.78 mEq/L    0.75-1.06 mEq/L\n  Creatinine                    1.88 mg/dL    \\<1.2 mg/dL\n  GFR                           36 mL/min     \\>90 mL/min\n  BUN                           60 mg/dL      14-46 mg/dL\n  Uric Acid                     4.6 mg/dL     3.0-6.9 mg/dL\n  Total Bilirubin               0.5 mg/dL     \\<1 mg/dL\n  Albumin                       4.0 g/dL      3.6-5.0 g/dL\n  Total Protein                 6.8 g/dL      6.5-8.7 g/dL\n  CRP                           0.19 mg/dL    \\<0.5 mg/dL\n  Transferrin                   269 mg/dL     200-360 mg/dL\n  Ferritin                      110 mcg/L     30-300 mcg/L\n  ALT                           339 U/L       \\<45 U/L\n  AST                           424 U/L       \\<50 U/L\n  GGT                           904 U/L       \\<55 U/L\n  Lipase                        61 U/L        \\<70 U/L\n  Thyroid-Stimulating Hormone   0.54 mIU/L    0.27-4.20 mIU/L\n  Hemoglobin                    14.5 g/dL     14.0-17.5 g/dL\n  Hematocrit                    43 %          40-52 %\n  Red Blood Cells               4.60 M/\u00b5L     4.6-6.2 M/\u00b5L\n  White Blood Cells             8.78 K/\u00b5L     4.5-11.0 K/\u00b5L\n  Platelets                     205 K/\u00b5L      150-400 K/\u00b5L\n  MCV                           94 fL         81-100 fL\n  MCH                           31.5 pg       27-34 pg\n  MCHC                          33.5 g/dL     32.4-35.0 g/dL\n  MPV                           11 fL         7-12 fL\n  RDW                           14.8 %        11.9-14.5 %\n  Neutrophils                   3.72 K/\u00b5L     1.8-7.7 K/\u00b5L\n  Lymphocytes                   2.37 K/\u00b5L     1.4-3.7 K/\u00b5L\n  Monocytes                     0.93 K/\u00b5L     0.2-1.0 K/\u00b5L\n  Eosinophils                   1.67 K/\u00b5L     \\<0.7 K/\u00b5L\n  Basophils                     0.09 K/\u00b5L     0.01-0.10 K/\u00b5L\n  Erythroblasts                 Negative      \\<0.01 K/\u00b5L\n  Antithrombin Activity         85 %          80-120 %\n\nThe GFR (Glomerular Filtration Rate) is 36 mL/min.\n\n**D**"
    },
    {
      "question_id": "patient_09_q11",
      "generated_text": "To answer this question, I will go through the provided texts to find the relevant information about Mr. Wells' lab results upon discharge.\n\nThe relevant text is: <text_3>\n\nIn this text, I found the following information:\n\n**Lab results upon Discharge:**\n\n  **Parameter**                    **Results**   **Reference Range**\n  -------------------------------- ------------- ---------------------\n  Sodium                           144 mEq/L     132-146 mEq/L\n  Potassium                        3.7 mEq/L     3.4-5.2 mEq/L\n  Calcium                          2.37 mEq/L    2.15-2.65 mEq/L\n  Chloride                         106 mEq/L     95-112 mEq/L\n  Inorganic Phosphate (PO4)         0.93 mEq/L    0.8-1.5 mEq/L\n  Transferrin Saturation           20 %          16-45 %\n  Magnesium                       0.78 mEq/L    0.75-1.06 mEq/L\n  Creatinine                      1.88 mg/dL    \\<1.2 mg/dL\n  GFR                             36 mL/min     \\<90 mL/min\n  BUN                             60 mg/dL      14-46 mg/dL\n  Uric Acid                       4.6 mg/dL     3.0-6.9 mg/dL\n  Total Bilirubin                 0.5 mg/dL     \\<1 mg/dL\n  Albumin                         4.0 g/dL      3.6-5.0 g/dL\n  Total Protein                   6.8 g/dL      6.5-8.7 g/dL\n  CRP                             0.19 mg/dL    \\<0.5 mg/dL\n  Transferrin                     269 mg/dL     200-360 mg/dL\n  Ferritin                        110 mcg/L     30-300 mcg/L\n  ALT                             339 U/L       \\<45 U/L\n  AST                             424 U/L       \\<50 U/L\n  GGT                             904 U/L       \\<55 U/L\n  Lipase                          61 U/L        \\<70 U/L\n  Thyroid-Stimulating Hormone     0.54 mIU/L    0.27-4.20 mIU/L\n  Hemoglobin                      14.5 g/dL     14.0-17.5 g/dL\n  Hematocrit                      43 %          40-52 %\n  Red Blood Cells                 4.60 M/\u00b5L     4.6-6.2 M/\u00b5L\n  White Blood Cells               8.78 K/\u00b5L     4.5-11.0 K/\u00b5L\n  Platelets                       205 K/\u00b5L      150-400 K/\u00b5L\n  MCV                             94 fL         81-100 fL\n  MCH                             31.5 pg       27-34 pg\n  MCHC                            33.5 g/dL     32.4-35.0 g/dL\n  MPV                             11 fL         7-12 fL\n  RDW                             14.8 %        11.9-14.5 %\n  Neutrophils                      3.72 K/\u00b5L     1.8-7.7 K/\u00b5L\n  Lymphocytes                     2.37 K/\u00b5L     1.4-3.7 K/\u00b5L\n  Monocytes                       0.93 K/\u00b5L     0.2-1.0 K/\u00b5L\n  Eosinophils                     1.67 K/\u00b5L     \\<0.7 K/\u00b5L\n  Basophils                       0.09 K/\u00b5L     0.01-0.10 K/\u00b5L\n  Erythroblasts                   Negative       \\<0.01 K/\u00b5L\n  Antithrombin Activity           85 %          80-120 %\n\n\nThe total bilirubin level is mentioned as: Total Bilirubin 0.5 mg/dL\n\nThe answer is: **A**"
    },
    {
      "question_id": "patient_09_q12",
      "generated_text": "Let's analyze the patient's situation step by step:\n\n1. Mr. Wells was admitted on 07/26/2019 with a suspected multifocal HCC segment and was referred to our hospital for further diagnostics.\n2. The patient had a history of chronic obstructive pulmonary disease (COPD) and was known to have multiple intrahepatic lesions in the right liver lobe (SIV, SVII/VIII).\n3. The patient's symptoms included persistent right-sided pain in the upper abdomen.\n4. Given the patient's history and symptoms, the most likely next step would be to conduct a diagnostic procedure to confirm the presence and extent of the liver lesions.\n\nConsidering the options provided, the most likely first diagnostic procedure would be an ultrasound-guided liver puncture to obtain a tissue sample for histological examination.\n\n**C**"
    },
    {
      "question_id": "patient_09_q13",
      "generated_text": "To find out when Atezolizumab/Bevacizumab was first administered to Mr. Wells, I will look for the date when this treatment was initiated.\n\nLooking at the provided text, I see that on 08/24/2019, Mr. Wells initiated treatment with Atezolizumab/Bevacizumab.\n\nThe correct answer is B."
    },
    {
      "question_id": "patient_09_q14",
      "generated_text": "To determine when Mr. Wells was first admitted for SIRT simulation, I will review the provided texts.\n\nText 0 mentions that a liver puncture, staging, and endoscopic exclusion of a primary in the gastrointestinal tract should be initiated after diagnostic clarification of the malignoma-specific findings. However, it does not specify when the SIRT simulation was performed.\n\nText 1 mentions that a DSA coeliac-mesenteric was performed on 08/13/2020, which was an uncomplicated SIRT simulation.\n\nText 2 mentions that a DSA coeliac-mesenteric angiography on 08/13/2020 was administered, which revealed a significant portion of radioactivity would reach the lung parenchyma during therapy, posing a risk of worsening his already compromised lung function.\n\nText 3 mentions that an attempt at SIRT simulation was made on 08/13/2019, but it was found to be an unsuitable treatment option.\n\nText 4 does not mention SIRT simulation.\n\nText 5 mentions that Mr. Wells complained about progressively worsening respiratory symptoms and was admitted to the hospital, but it does not mention SIRT simulation.\n\nText 6 mentions that Mr. Wells was under inpatient treatment from 02/04/2021 to 02/12/2021, but it does not mention SIRT simulation.\n\nBased on the information provided, the first admission for SIRT simulation was on 08/13/2019, but it was not feasible.\n\nHowever, the actual SIRT simulation attempt was made on 08/13/2019, but the correct answer should be the date of the attempt, which is 08/13/2019."
    },
    {
      "question_id": "patient_09_q15",
      "generated_text": "To determine the correct sequence of imaging tests conducted on 11/20/2020 for Mr. Wells, let's consider the information provided:\n\n1. The text mentions that an MRI Liver (plain + contrast agent) was conducted on 11/20/2020 at 09:01 AM.\n2. Later, it mentions that a CT Chest/Abdomen/Pelvis with contrast agent was conducted on 11/20/2020 at 12:45 PM.\n3. There is also a mention of Gastroscopy on 11/20/2020 at 13:45 PM and Colonoscopy on 11/20/2020 at 15:15 PM.\n\nGiven this information, the sequence of imaging tests conducted on 11/20/2020 for Mr. Wells would be: MRI Liver followed by CT Chest/Abdomen/Pelvis, and then Gastroscopy and Colonoscopy were conducted later in the day.\n\n**A**"
    },
    {
      "question_id": "patient_09_q16",
      "generated_text": "To find the correct answer, I will follow the steps below:\n\n1. I will look for the text related to Mr. Wells in the provided texts.\n2. I will search for the text that mentions the liver tumor board decision for systemic therapy.\n3. I will identify the date mentioned in that text as the correct answer.\n\nText ID patient_0 is related to Mr. Wells.\n\nIn text ID patient_0, I find the following relevant text:\n\"Decision from the Liver Tumor Board on 08/18/2019: Recommending systemic therapy.\"\n\nSo, the liver tumor board decision for systemic therapy was made on 08/18/2019.\n\n**B**"
    },
    {
      "question_id": "patient_09_q17",
      "generated_text": "To determine the correct chronological order of the first set of diagnostic procedures following Mr. Wells' admission on 07/26/2019, let's break down the information provided in the text.\n\n1. The patient underwent a diagnostic ureterorenoscopy on 01/16/2019, which is not the focus of this question.\n2. However, we are looking for the sequence of diagnostic procedures starting from 07/26/2019.\n3. On 07/26/2019, an ultrasound-guided liver puncture was performed.\n4. Following the ultrasound-guided liver puncture, an MRI Liver was conducted.\n5. Then, a CT Thorax/Abdomen/Pelvis was performed.\n\nBased on this information, the correct sequence of the first set of diagnostic procedures following Mr. Wells' admission on 07/26/2019 is:\n\nUltrasound-guided liver puncture, MRI Liver, CT Thorax/Abdomen/Pelvis\n\nSo, the answer is: **C**"
    },
    {
      "question_id": "patient_09_q18",
      "generated_text": "To determine the primary reason for the intermittent pause and resumption of Atezolizumab/Bevacizumab therapy in Mr. Wells' case, we need to analyze the information provided in the medical history and therapy progression.\n\nStep 1: Review the therapy history of Mr. Wells, which includes initiation of Atezolizumab/Bevacizumab on 08/24/2019, a pause starting on 09/17/2019 due to transaminase elevation, and subsequent re-administration on 01/25/2022 and 02/16/2022.\n\nStep 2: Analyze the reasons for the pause in therapy. The text mentions \"transaminase elevation\" as the reason for the pause starting on 09/17/2019.\n\nStep 3: Eliminate options that are not supported by the information provided. Options A, C, and E are not supported by the text, as there is no mention of HCC progression, detection of Streptococcus pneumoniae in sputum cultures, or the patient's personal preference as reasons for the pause.\n\nStep 4: Choose between options B and D, which are the remaining possibilities. While option B mentions pulmonary complications requiring steroid therapy, the text does not specifically mention pulmonary complications as the reason for the pause. However, it does mention that the patient experienced transient worsening of lung function with steroid requirement after Atezolizumab/Bevacizumab administrations, which could be related to option B. On the other hand, option D, \"fluctuations in liver function tests indicating possible drug-induced hepatitis,\" is not mentioned in the text as the reason for the pause.\n\nStep 5: Given the information provided, it seems that the pause in therapy was likely due to a combination of factors, but the primary reason mentioned is \"transaminase elevation,\" which is more closely related to liver function tests and possible drug-induced hepatitis (option D).\n\n**D**"
    },
    {
      "question_id": "patient_09_q19",
      "generated_text": "To determine the correct chronological sequence of the radiology imaging examinations that Mr. Wells underwent, let's analyze the information provided:\n\n1. The patient underwent a liver puncture, staging, and endoscopic exclusion of a primary in the gastrointestinal tract (text_0). This suggests that the imaging examinations were conducted in the context of evaluating a liver condition, likely hepatocellular carcinoma.\n\n2. The patient underwent an ultrasound on 07/26/2019 (text_0). This is the first imaging examination mentioned.\n\n3. The patient then underwent a MRI of the liver (text_1) and CT Chest/Abdomen/Pelvis (text_1) on 07/26/2019 and 07/27/2019, respectively. These examinations were conducted on the same day as the ultrasound.\n\n4. The patient underwent gastroscopy (text_1) and colonoscopy (text_1) on 07/28/2019. These examinations were conducted after the CT Chest/Abdomen/Pelvis.\n\n5. The patient underwent DSA Coeliac-Mesenteric (text_2) and Perfusion Scintigraphy of the Liver and Lungs with SPECT/CT (text_2) on 08/13/2019. These examinations were conducted after the gastroscopy and colonoscopy.\n\n6. The patient underwent MRI liver (text_3) and CT Chest/Abdomen/Pelvis (text_3) on 10/24/2020. These examinations were conducted after the DSA Coeliac-Mesenteric and Perfusion Scintigraphy of the Liver and Lungs with SPECT/CT.\n\n7. The patient underwent pulmonary function testing (text_4) on 11/20/2020. This examination was conducted after the MRI liver and CT Chest/Abdomen/Pelvis.\n\n8. The patient underwent gastroscopy (text_4) and colonoscopy (text_4) on 11/20/2020. These examinations were conducted after the pulmonary function testing.\n\nTherefore, the correct chronological sequence of the radiology imaging examinations that Mr. Wells underwent is:\n\nUltrasound < Liver MRI < CT Chest/Abdomen/Pelvis < Gastroscopy < Colonoscopy < DSA Coeliac-Mesenteric < Perfusion Scintigraphy of the Liver and Lungs with SPECT/CT < MRI liver < CT Chest/Abdomen/Pelvis < Pulmonary function testing < Gastroscopy < Colonoscopy\n\nThe correct answer is B."
    },
    {
      "question_id": "patient_10_q0",
      "generated_text": "To determine when Mr. Rudolph underwent atrial fibrillation ablation, I need to analyze the provided text for the patient ID patient_10, which is actually text_2.\n\nIn text_2, under the section \"Current Medication:\", I see a list of medications, and under \"Medication:\", I see \"Aspirin 100 mg 1-0-0, Bisoprolol (Zebeta) 50 mg 1/2-0-0, Pantoprazole (Protonix) 40 mg 1-0-0, Prednisolone (Prelone) 80 mg According to scheme\". However, I don't see any information about atrial fibrillation ablation in this section.\n\nThen, I look at the \"Other Diagnoses:\" section, where I see \"2013: Atrial fibrillation with ablation\". This indicates that Mr. Rudolph underwent atrial fibrillation ablation in 2013.\n\nSo, the answer is: C"
    },
    {
      "question_id": "patient_10_q1",
      "generated_text": "To answer this question, I will follow these steps:\n\n1.  Look for information about Mr. Rudolph's medical history.\n2.  Identify the procedure performed in 2010.\n\nFrom the provided text, I found the following information about Mr. Rudolph's medical history:\n\n-   2013: Atrial fibrillation with ablation\n-   2010: pTCA stenting for acute myocardial infarction/CHD\n-   2012: Laparoscopic cholecystectomy\n-   Tonsillectomy (date unknown)\n-   01/2019: Left psoas abscess with detection of multisensitive Staphylococcus aureus\n\nBased on this information, I found that in 2010, Mr. Rudolph underwent a pTCA stenting for acute myocardial infarction/CHD.\n\n**B**"
    },
    {
      "question_id": "patient_10_q2",
      "generated_text": "To determine the correct answer, let's break down the information provided in the text:\n\n1. The text mentions that Mr. Rudolph was under our care from 01/16/2019 to 01/17/2019.\n2. It states that he was diagnosed with urothelial carcinoma of the renal pelvis and underwent a diagnostic ureterorenoscopy on 01/16/2019.\n\nBased on this information, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_10_q3",
      "generated_text": "To find the correct answer, I will follow these steps:\n\n1.  Find the relevant text in the given context that mentions the number of biopsies taken during the ureterorenoscopy of Mr. Rudolph.\n2.  Read the text to determine the correct number of biopsies.\n\nThe relevant text is from the context <text_0> and specifically from the section labeled **Procedure:**\n\n\"The patient underwent a diagnostic ureterorenoscopy, which proceeded without complications. During the procedure, a total of eight biopsies were successfully obtained from the ureter for histological evaluation.\"\n\nBased on this information, I can determine that the correct answer is:\n\nC"
    },
    {
      "question_id": "patient_10_q4",
      "generated_text": "To determine which procedure was NOT performed on Mr. Rudolph on 01/16/2019, let's review the provided information.\n\nAccording to the text, on 01/16/2019, the following procedures were performed on Mr. Rudolph:\n\n- Diagnostic ureterorenoscopy on the left\n- Biopsy of the left ureter\n- Retrograde urography on the left\n- DJ catheter placement on the left\n\nHowever, there is no mention of a laparoscopic cholecystectomy being performed on 01/16/2019. A laparoscopic cholecystectomy is mentioned in the patient's history as a procedure performed in 2012.\n\nTherefore, the correct answer is:\n\nE"
    },
    {
      "question_id": "patient_10_q5",
      "generated_text": "To answer this question, I need to find the relevant text related to the patient ID patient_10, Name: Peter Rudolph, Birthday: 05/26/1954, and Diagnosis: Renal cell carcinoma.\n\nThe relevant text is in text_0:\n**Main Diagnosis and Main Procedure from the Surgical Report:**\n\n-   Surgical Diagnosis: Unclear proximal ureter tumor on the left\n\n-   Unclear tumor in the left renal pelvis\n\n-   Surgical Procedure: Diagnostic ureterorenoscopy on the left\n\n-   Biopsy of the left ureter\n\n-   Retrograde urography on the left\n\n-   DJ catheter placement on the left\n\n-   Diagnostic urethroscopy\n\n**Procedure:**\n\nThe patient underwent a diagnostic ureterorenoscopy, which proceeded without complications. During the procedure, a total of eight biopsies were successfully obtained from the ureter for histological evaluation. Cytological samples were also collected from both the ureter and renal pelvis. Although there was a stenosing tumor present, endoscopic passage into the renal pelvis was successfully accomplished.\n\nFollowing the diagnostic procedure, a left-sided double-J catheter was placed under radiographic control. Additionally, a urinary catheter was inserted. It was observed that the initial urine output appeared hemorrhagic, but it subsequently cleared to a normal coloration.\n\nFor post-procedural management, plans are in place for the DJ catheter to be removed, the timing of which will be guided by improvements in the color of the urine as well as the patient's overall clinical status. A sonogram will be performed prior to discharge as part of routine follow-up. Moreover, the patient has been scheduled for counseling to address the significantly elevated PSA values noted in recent lab tests.\n\n**Internal Cytological Report Clinical Details: Sample Date: 01/16/2019**\n\n1.  Left ureter (100 mL colorless, clear)\n\n2.  Left renal pelvis (50 mL brown) (Papanicolaou staining)\n\nBoth materials contain increased urinary sediment, along with granulocytes, erythrocytes, and urothelial cells from various layers with multi-nuclear surface cells. Material 1 also shows papillary arrangements of urothelial cells, some of which have peripheral hyperchromatic cell nuclei and altered nuclear-plasma ratios. Material 2 shows individual papillary urothelial cell arrangements with similar nuclear quality, hyperchromasia, and eccentric placement within the cytoplasm, as well as nuclear rounding. Numerous individual urothelial cells are also present with significantly rounded and enlarged cell nuclei, frequently in a peripheral location with hyperchromasia.\n\n**Critical Findings Report:**\n\n1.  Detection of a papillary-structured urothelial population with nuclear changes, which may be related to instrumentation. Malignant urothelial proliferation cannot be definitively ruled out.\n\n2.  Abundant cell material with papillary and single atypical urothelia, highly suspicious for urothelial carcinoma cells.\n\n**Diagnostic Classification:** Suspicious\n\nNow, I need to find the text that mentions the antibiotic used for antibacterial prophylaxis during the ureterorenoscopy. The text is in text_0:\n**Procedure:**\n\nThe patient underwent a diagnostic ureterorenoscopy, which proceeded without complications. During the procedure, a total of eight biopsies were successfully obtained from the ureter for histological evaluation. Cytological samples were also collected from both the ureter and renal pelvis. Although there was a stenosing tumor present, endoscopic passage into the renal pelvis was successfully accomplished.\n\nFollowing the diagnostic procedure, a left-sided double-J catheter was placed under radiographic control. Additionally, a urinary catheter was inserted. It was observed that the initial urine output appeared hemorrhagic, but it subsequently cleared to a normal coloration.\n\nFor post-procedural management, plans are in place for the DJ catheter to be removed, the timing of which will be guided by improvements in the color of the urine as well as the patient's overall clinical status. A sonogram will be performed prior to discharge as part of routine follow-up. Moreover, the patient has been scheduled for counseling to address the significantly elevated PSA values noted in recent lab tests.\n\n**Procedure:**\n\nThe text does not explicitly mention the antibiotic used for antibacterial prophylaxis during the ureterorenoscopy.\n\nHowever, I can find the text in text_1:\n**Fast Track Report on 03/18/2019: **\n\n**Microscopy:** Histologically, there are extensive infiltrations of a carcinoma growing in large solid formations with focal necrosis and highly pleomorphic cell nuclei. In block 1A, there is a section of a urothelium-lined duct structure with a transition from normal epithelium to highly atypical epithelium and invasive carcinoma infiltrates. Broad infiltration into adjacent fat tissue and renal parenchyma is observed. Focal perineural sheath infiltration.\n\nHowever, this text does not mention the antibiotic used during the ureterorenoscopy either.\n\nI can find the text in text_0 again:\n**Procedure:**\n\nThe patient underwent a diagnostic ureterorenoscopy, which proceeded without complications. During the procedure, a total of eight biopsies were successfully obtained from the ureter for histological evaluation. Cytological samples were also collected from both the ureter and renal pelvis. Although there was a stenosing tumor present, endoscopic passage into the renal pelvis was successfully accomplished.\n\nFollowing the diagnostic procedure, a left-sided double-J catheter was placed under radiographic control. Additionally, a urinary catheter was inserted. It was observed that the initial urine output appeared hemorrhagic, but it subsequently cleared to a normal coloration.\n\nFor post-procedural management, plans are in place for the DJ catheter to be removed, the timing of which will be guided by improvements in the color of the urine as well as the patient's overall clinical status. A sonogram will be performed prior to discharge as part of routine follow-up. Moreover, the patient has been scheduled for counseling to address the significantly elevated PSA values noted in recent lab tests.\n\n**Report:** Indication: Unclear mass in the left renal pelvis. Elective diagnostic ureterorenoscopy for further assessment. Written consent is obtained. The urine is sterile. The procedure is conducted under antibacterial prophylaxis with Ampicillin/Sulbactam 3g.\n\nNow I found the text that mentions the antibiotic used for antibacterial prophylaxis during the ureterorenoscopy. The answer is C."
    },
    {
      "question_id": "patient_10_q6",
      "generated_text": "To determine the correct answer, let's review the information provided in the text.\n\nThe relevant text is from <text_0> and <text_1>. In <text_0>, there is no information about the cytological report date. However, in <text_1>, the cytological report is mentioned, and the date is provided as \"Sample Date: 01/16/2019\".\n\nTherefore, the correct answer is:\n\nB"
    },
    {
      "question_id": "patient_10_q7",
      "generated_text": "To determine the correct answer, let's analyze the information provided in the internal cytological report.\n\nThe report mentions that the left ureter and renal pelvis contained increased urinary sediment, along with granulocytes, erythrocytes, and urothelial cells from various layers with multi-nuclear surface cells. Material 1 also shows papillary arrangements of urothelial cells, some of which have peripheral hyperchromatic cell nuclei and altered nuclear-plasma ratios. Material 2 shows individual papillary urothelial cell arrangements with similar nuclear quality, hyperchromasia, and eccentric placement within the cytoplasm, as well as nuclear rounding. Numerous individual urothelial cells are also present with significantly rounded and enlarged cell nuclei, frequently in a peripheral location with hyperchromasia.\n\nBased on this information, the correct answer is:\n\nB. Altered nuclear plasma ratios"
    },
    {
      "question_id": "patient_10_q8",
      "generated_text": "To answer the question, let's look at the provided text and follow the steps:\n\n1. The patient is Mr. Peter Rudolph, born on 05/26/1954.\n2. The diagnosis is renal cell carcinoma.\n3. The relevant text for this question is from the section <text_1> and <text_2>.\n4. In <text_1>, the \"Fast Track Report on 03/18/2019\" mentions \"Macroscopy: Left renal pelvis carcinoma (left kidney): Extensive infiltration of a high-grade urothelial carcinoma in the renal pelvis with infiltration of the renal parenchyma and perihilar adipose tissue, maximum size 4.3 cm (1.).\"\n5. Therefore, the size of the left renal pelvis mass is 4.3 cm.\n\n**C**"
    },
    {
      "question_id": "patient_10_q9",
      "generated_text": "To determine how much the liver metastasis in segment VII grew in largest diameter between 03/03/2021 and 06/07/2021, we need to compare the sizes of the metastasis at these two dates.\n\nFrom the text, we can see that on 03/03/2021, the metastasis in segment VII was 1.2 x 1.1 cm, and on 06/07/2021, it was 3.3 x 2.4 cm.\n\nTo find the change in size, we need to find the difference in the largest diameter, which is the diameter of the metastasis in the direction of its longest axis. \n\nThe largest diameter of the metastasis on 03/03/2021 was 1.2 cm, and the largest diameter of the metastasis on 06/07/2021 was 2.4 cm. \n\nThe difference in the largest diameter is 2.4 cm - 1.2 cm = 1.2 cm. However, this is not the correct answer choice. We need to calculate the difference in the largest diameter of the metastasis in segment VII between 03/03/2021 and 06/07/2021 based on the provided answer choices.\n\nGiven the provided answer choices, we need to compare the sizes of the metastasis at these two dates again. The metastasis in segment VII on 03/03/2021 was 1.2 x 1.1 cm, and on 06/07/2021, it was 3.3 x 2.4 cm.\n\nThe largest diameter of the metastasis on 03/03/2021 was 1.2 cm, and the largest diameter of the metastasis on 06/07/2021 was 3.3 cm. \n\nThe difference in the largest diameter is 3.3 cm - 1.2 cm = 2.1 cm, which is not among the provided answer choices. However, we can calculate the difference in the largest diameter of the metastasis in segment VII between 03/03/2021 and 06/07/2021 based on the provided answer choices.\n\nThe metastasis in segment VII on 03/03/2021 was 1.2 x 1.1 cm, and on 06/07/2021, it was 5.8 x 3.6 cm.\n\nThe largest diameter of the metastasis on 03/03/2021 was 1.2 cm, and the largest diameter of the metastasis on 06/07/2021 was 5.8 cm.\n\nThe difference in the largest diameter is 5.8 cm - 1.2 cm = 4.6 cm. However, the closest answer choice is not available, but we can see that the metastasis in segment VII grew significantly. The closest answer choice to this growth is 5.6 cm, so I will choose that as my answer.\n\nC."
    },
    {
      "question_id": "patient_10_q10",
      "generated_text": "To determine which medication was not part of Mr. Rudolph's regimen upon discharge in 06/29/2021, we need to look at the medication list provided in the text_4 section, which is dated 06/29/2021.\n\nThe medications listed are:\n\n- Aspirin\n- Bisoprolol\n- Pantoprazole\n- Prednisolone\n\nMetformin is not mentioned in the provided text as part of Mr. Rudolph's regimen upon discharge on 06/29/2021.\n\nTherefore, the correct answer is: \nE"
    },
    {
      "question_id": "patient_10_q11",
      "generated_text": "To answer this question, let's analyze the updates provided for Mr. Rudolph:\n\n1. In the first update, it is mentioned that Mr. Rudolph underwent left nephroureterectomy with the detection of urothelial carcinoma of the renal pelvis, and then received four cycles of adjuvant chemotherapy with Gemcitabine/Cisplatin.\n\n2. In the second update, it is mentioned that Mr. Rudolph received 10 cycles of immunotherapy with Nivolumab 240 mg q14d.\n\n3. In the third update, it is mentioned that Mr. Rudolph received third-line chemotherapy with Vinflunin, resulting in hepatic progression.\n\n4. In the fourth update, it is mentioned that Mr. Rudolph was presented to the urological-interdisciplinary conference for reevaluation and discussion of further procedures, and the recommended options included chemotherapy with Gemcitabine and Paclitaxel, best-supportive-care strategy with symptom-oriented approach, and targeted therapy with Enfortumab Vedotin.\n\nBased on these updates, we can see that:\n\n- Gemcitabine/Cisplatin (A) has been administered to Mr. Rudolph.\n- Nivolumab (B) has been administered to Mr. Rudolph.\n- Immunotherapy (C) has been administered to Mr. Rudolph, as Nivolumab is a type of immunotherapy.\n- Chemotherapy with Vinflunin (E) has been administered to Mr. Rudolph.\n\nHowever, Enfortumab Vedotin (D) is not mentioned as a therapy that has been administered to Mr. Rudolph.\n\n**D**"
    },
    {
      "question_id": "patient_10_q12",
      "generated_text": "To determine the correct answer, let's analyze the information step by step:\n\n1. The Fist Closure Test was performed on Mr. Rudolph.\n2. The test was conducted to assess a potential left subclavian stenosis with blood pressure side differences.\n3. The test results showed bilateral triphasic flow in the subclavian arteries.\n4. There was no evidence of subclavian stenosis, reversed flow in the left vertebral artery, or blood pressure differences between the right and left arms.\n5. Arm claudication was denied by the patient.\n\nBased on the analysis, the correct answer is:\n\nA"
    },
    {
      "question_id": "patient_10_q13",
      "generated_text": "To determine which option is NOT a part of Mr. Rudolph's medical history, I will review the provided medical history.\n\nMr. Rudolph's medical history includes:\n\n- 03/19: Left nephroureterectomy with the detection of urothelial carcinoma of the renal pelvis and adrenal metastasis\n- 04/19 - 07/19: Four cycles of adjuvant chemotherapy with Gemcitabine/Cisplatin\n- 04/20: Newly emerged liver metastasis in Segment 6 and Segment 7\n- 05/20 - 09/20: 10 cycles of immunotherapy with Nivolumab 240 mg q14d\n- 2013: Atrial fibrillation with ablation\n- 2010: pTCA stenting for acute myocardial infarction/CHD\n- Suspected activated soft tissue rheumatism (currently under Prednisolone pulse therapy)\n- Unclear thyroid nodule\n- 2012: Laparoscopic cholecystectomy\n- Tonsillectomy\n- 01/2019: Left psoas abscess with detection of multisensitive Staphylococcus aureus\n\nNow, I will review the options:\n\nA. Atrial fibrillation with ablation - This is part of Mr. Rudolph's medical history.\nB. pTCA stenting for acute myocardial infarction/CHD - This is also part of Mr. Rudolph's medical history.\nC. Laparoscopic cholecystectomy - This is part of Mr. Rudolph's medical history.\nD. Left psoas abscess - This is part of Mr. Rudolph's medical history.\nE. Prostatectomy - There is no mention of a prostatectomy in Mr. Rudolph's medical history.\n\n**E**"
    },
    {
      "question_id": "patient_10_q14",
      "generated_text": "To answer the question, we need to look at the last medical report provided for Mr. Rudolph, which is text_4.\n\nIn text_4, under the section \"Medication upon Discharge:\", the medications prescribed to Mr. Rudolph are listed as:\n\n  **Medication **           **Dosage**   **Frequency**\n  ------------------------- ------------ ---------------\n  Aspirin                   100 mg       1-0-0\n  Bisoprolol (Zebeta)       50 mg        1/2-0-0\n  Pantoprazole (Protonix)   40 mg        1-0-0\n  Prednisolone (Prelone)    80 mg        According to scheme\n\nBased on this information, we can see that Mr. Rudolph was prescribed Aspirin, Bisoprolol, and Pantoprazole, along with Prednisolone.\n\nTherefore, the correct answer is B."
    },
    {
      "question_id": "patient_10_q15",
      "generated_text": "To determine which surgical procedure Mr. Rudolph underwent in February 2022, I will follow these steps:\n\n1.  Review the provided text and identify any information related to Mr. Rudolph's February 2022 hospital stay.\n2.  Look for a specific surgical procedure mentioned in the text for that time period.\n\nFrom the text, I found the following relevant information:\n\n<text_6>\n**Dear colleague, **\n\nWe report to you about Mr. Peter Rudolph, born on 05/26/1954, who was in our inpatient treatment from 02/22/2022 to 02/29/2022.\n\n**Diagnosis**: Symptomatic incisional hernia in the area of the old laparotomy scar (status post left nephroureterectomy in 03/19.\n\n**Other Diagnoses:**\n\n-   03/19: Left nephroureterectomy with the detection of urothelial carcinoma of the renal pelvis and adrenal metastasis, pT3, pN0, (0/11), M1 (ADR), pn1, L1, V1, high-grade\n\n-   04/19 - 07/19: Four cycles of adjuvant chemotherapy with Gemcitabine/Cisplatin\n\n-   04/20: Newly emerged liver metastasis in Segment 6 and Segment 7\n\n-   05/20 - 09/20: 10 cycles of immunotherapy with Nivolumab 240 mg q14d\n\n<!-- -->\n\n-   2013: Atrial fibrillation with ablation\n\n-   2010: pTCA stenting for acute myocardial infarction/CHD\n\n-   Suspected activated soft tissue rheumatism (currently under Prednisolone pulse therapy)\n\n-   Unclear thyroid nodule\n\n-   2012: Laparoscopic cholecystectomy\n\n-   Tonsillectomy\n\n-   01/2019: Left psoas abscess with detection of multisensitive Staphylococcus aureus\n\n**Operation:** Alloplastic Incisional Hernia Repair in intubation anesthesia on 02/23/2022.\n\nThe text specifically mentions that Mr. Rudolph underwent an \"Alloplastic Incisional Hernia Repair\" on February 23, 2022.\n\n**B**"
    },
    {
      "question_id": "patient_10_q16",
      "generated_text": "To answer this question, we need to find information about the chemotherapy regimen that Mr. Rudolph was initially treated with after his diagnosis of renal cell carcinoma.\n\nFrom the given texts, we can see that Mr. Rudolph was diagnosed with renal cell carcinoma (urothelial carcinoma of the renal pelvis) in March 2019. In the text <text_2>, it is mentioned that Mr. Rudolph underwent four cycles of adjuvant chemotherapy with Gemcitabine/Cisplatin after his nephroureterectomy.\n\nSo, the correct answer is:\n\nD"
    },
    {
      "question_id": "patient_10_q17",
      "generated_text": "To determine which immunotherapy Mr. Rudolph was administered from May to September 2020, I will follow these steps:\n\n1. Review the provided texts for any mention of Mr. Rudolph's treatment from May to September 2020.\n2. Look for any information about the specific immunotherapy he received during that time period.\n\nFrom the provided texts, I can see that in text_2, it mentions Mr. Rudolph's treatment history, including his cancer diagnosis and treatment plan. In the section \"Medical History,\" it is mentioned that \"04/20: Newly emerged liver metastasis in Segment 6 and Segment 7. 05/20 - 09/20: 10 cycles of immunotherapy with Nivolumab 240 mg q14d.\"\n\nBased on this information, I can determine that Mr. Rudolph was administered Nivolumab from May to September 2020.\n\n**D**"
    },
    {
      "question_id": "patient_10_q18",
      "generated_text": "To determine the change in Mr. Rudolph's medication plan between 06/29/2021 and 02/22/2022, we need to compare the medication lists from both dates.\n\nOn 06/29/2021, the medication plan included:\n- Aspirin (100 mg, 1-0-0)\n- Bisoprolol (50 mg, 1/2-0-0)\n- Pantoprazole (40 mg, 1-0-0)\n- Prednisolone (80 mg, according to scheme)\n\nOn 02/22/2022, the medication plan included:\n- Aspirin (100 mg, 1-0-0)\n- Bisoprolol (50 mg, 1/2-0-0)\n\nComparing the two medication lists, we can see that Pantoprazole and Prednisolone were removed from the medication plan.\n\n**E**"
    },
    {
      "question_id": "patient_10_q19",
      "generated_text": "To determine the correct sequence of radiology imaging examinations that Mr. Rudolph underwent, we need to analyze the provided information. \n\nAccording to the text, the examinations were:\n\n1. CT Thorax (plain) on 06/07/2021\n2. External CT Abdomen dated 06/07/2021\n3. CT-guided liver biopsy on 11/04/2020\n\nBased on this information, the correct sequence is: \n\nCT Thorax (plain) < External CT Abdomen < CT-guided liver biopsy\n\nSo, the answer is B."
    }
  ]
}